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Pharmacological activityIn addition to thousands of research papers related to resveratrol (RSV), approximately 300 review articles have
been published. Earlier research tended to focus on pharmacological activities of RSV related to cardiovascular
systems, inﬂammation, and carcinogenesis/cancer development. More recently, the horizon has been broadened
by exploring the potential effect of RSV on the aging process, diabetes, neurological dysfunction, etc. Herein, we
primarily focus on the in vivo pharmacological effects of RSV reported over the past 5 years (2009–2014). In
addition, recent clinical intervention studies performed with resveratrol are summarized. Some discrepancies
exist between in vivo studies with animals and clinical studies, or between clinical studies, which are likely
due to disparate doses of RSV, experimental settings, and subject variation. Nevertheless, many positive
indications have been reported with mammals, so it is reasonable to advocate for the conduct of more deﬁnitive
clinical studies. Since the safety proﬁle is pristine, an added advantage is the use of RSV as a dietary supplement.
This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical ﬁndings to
improved patient outcomes.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Resveratrol (RSV) was ﬁrst isolated in 1939 by Takaoka from
Veratrum grandiﬂorum Loes. ﬁl. (the root of the white hellebore) [1]. It
is speculated that the name resveratrol was derived from the combina-
tion of its chemical structure and plant source used for isolation: a resor-
cinol derivative or polyphenol in the resin, occurring in Veratrum species
which contains hydroxyl (–OH) groups (-ol). In addition to themost pop-
ular name, resveratrol, further nomenclature includes trans-resveratrol,
(E)-resveratrol, 3,4′,5-trihydroxy-trans-stilbene, 3,4′,5-stilbenetriol, (E)-
3,4′,5-trihydroxystilbene, trans-3,5,4′-trihydroxystilbene, 5-[(1E)2-(4-
hydroxyphenyl)ethenyl]1,3-benzenediol, (E)2-(3,5-dihydroxyphenyl)1-
(4-hydroxyphenyl)ethane, (E)5-(p-hydroxystyryl)resorcinol, Bioforte™,
Regu®-Fade (for skin), resVida™, and SRT 501.
As a defense mechanism in plants, the production of RSV, one of the
phytoalexins, can be triggered in response to fungi, rhizobacteria, UV
irradiation, metallic salts, methyl jasmonate, etc. The main enzyme re-
sponsible for RSV biosynthesis is stilbene synthase which condenses
one p-coumaroyl-CoA (4-coumaroyl-CoA) and three molecules of
malonyl-CoA [2]. Stilbene synthase encoding genes have been identiﬁed
in grapevine, pine, Arachis hypogea, Parthenocissus henryana, Vitis riparia
cv Gloire de Montpellier, Sorghum, etc. [3].atrol: Challenges in translating
ege of Pharmacy, University of
USA. Tel.: +1 808 933 2909;Despite the early discovery, RSV gained little attention until an arti-
cle coining the phrase ‘the French paradox’ was published, in which it
was suggested that people of France, who consume a relatively high
level of saturated fat, had a relatively low mortality from coronary
heart disease, presumably as a result of wine consumption [4]. Later,
RSV was touted as an active ingredient in red wine responsible for
reduced serum lipids [5], but of course the concentration of RSV in
wine is relatively low [6], and grapes are known to contain over 1600
phytochemicals [7]. As shown in Fig. 1, there has been an enormous
upsurge of studies investigating the characteristics of RSV since 1997,
undoubtedly due to the publication or our paper reporting cancer
chemopreventive potential with a number of model systems [8].
Based on a search using SciFinder® [accessed July 18, 2014, using the
RSV chemical structure (CAS 501-36-0)], 219 commercial sources are
available and 679 reactions to yield RSV have been published. A large
number of patents have been ﬁled that are related to the effects of
RSV in therapeutic, cosmetic and nutraceutical applications [9]. The
response of the nutraceutical industry has been robust. Many dietary
supplements containing RSV as a single component or in combination
with other ingredients are on the market. Unit doses range from about
0.2 to 1000 mg (Google search, July 19, 2014). In some products RSV
is encapsulated in liposomal formulations, micronized, or ﬁlled as a
liquid capsule, ostensibly to improve the absorption.
In addition, a wide array of compounds and extracts are used in com-
binationwith RSV, including: compounds such as glucosamine, ﬂavonoids
(e.g., quercetin, catechins, rutin, anthocyanins, and proanthocyanidins),
stilbenoids (e.g., piceid), phenolic acids (e.g., ellagic acid), vitamins
(e.g., vitamins B6, B12 and C, folic acid, and coenzyme Q10), phos-
phatidylcholine, piperine, tocotrienols, lutein, lycopene, fatty acids
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Fig. 1. Yearly publications related to RSV (1990–2014). The original search with the chemical structure of RSV (CAS number 501-36-0) followed by the removal of duplicate articles using
the SciFinder® program yielded a total of 15,782 references (accessed July 18, 2014) as shown in ‘total’ bar (shaded). Within the 15,782 references, a total of 6664 articles include ‘resver-
atrol’ in the title (‘title’ bar, open).
1072 E.-J. Park, J.M. Pezzuto / Biochimica et Biophysica Acta 1852 (2015) 1071–1113(e.g., docosahexaenoic acid, eicosapentaenoic acid), L-carnitine, and
reduced L-glutathione; extracts from kelp, acai berry, blueberry, cherry,
cranberry, pomegranate, olive, citrus fruits, melon, grape, French red
wine, turmeric rhizome, black pepper fruit, potato, or calamari oil.
Also, RSV has been used as an active ingredient in skin care products,
with vitamin C, calcium, methylsulfonylmethane, polyphenols, or
proanthocyanidins.
Although scores of in vitro studies have added to our understanding
of the vast biological potential of RSV, it is common to use high concen-
trations that may not be of physiological relevance. Since RSV is known
to have poor bioavailability in that it is rapidly metabolized and excret-
ed, it is expected that the results of many in vitro studies will not have a
good correlation with in vivo studies. Here, the discussion is limited to
the in vivo biological effects of RSV, excluding work in which extracts
or mixtures of compounds were investigated.
The review is largely based on a PubMed search using the search
terms as ‘resveratrol and animal model’, ‘resveratrol and in vivo’, or
‘resveratrol and animal study’. A literature search using SciFinder®
(research topic: resveratrol, document type: review, publication
year: –2008, accessed November 22, 2014) resulted in 244 review
articles that include “resveratrol” in the titles. As an attempt to avoid
redundancy, this article focuses on in vivo studies that were published
during the time period of 2009 to 2014.
2. Carcinogenesis/cancer
Studies on the cancer chemopreventive effect of RSV increased
dramatically following the paper published in 1997 describing the
ability of RSV to inhibit skin carcinogenesis in an animal model [8].
Since comprehensive reviews on the cancer chemopreventive and
anti-cancer potential of RSV have been published, we currently summa-
rize data appearing over the past 5 years. Molecular alterations observed
with different carcinogenesis/cancer models (including lung, breast,
prostate and colon) are illustrated in Fig. 2.
2.1. Skin
The ﬁrst report on the cancer chemopreventive potential of RSVwas
against skin carcinogenesis [8]. In rodent models, skin cancer can be in-
duced by the treatment with 7,12-dimethylbenz[a]anthracene (DMBA)
plus 12-O-tetradecanoylphorbol-13-acetate (TPA), benzo[a]pyrene (BP),and UV irradiation [10,11]. To evaluate the skin cancer chemopreventive
or anti-cancer capacity of RSV, in vivo studies have been conducted using
DMBA/TPA [8,12–16], DMBA alone [17–21], TPA alone [22–24], DMBA/
croton oil [25], UVB exposure [26–29], BP [18], and xenograft [30]models.
Topical application of RSV is themost commonly used route of treatment
in skin cancer models. In DMBA/TPA models, RSV treatment reduced the
incidence [8,12–15],multiplicity [8,12,14,15], and tumor volume [14–16],
and delayed the onset of tumorigenesis [14]. At biomarker levels, RSV
induced apoptosis: RSV decreased the expression levels of Bcl-2 while it
increased p53 and Bax. Also, RSV enhanced the release of cytochrome c,
induced apoptotic protease-activating factor-1(APAF-1), and cleaved
caspase-9,-3, and poly (ADP-ribose) polymerase (PARP) [14]. On the
other hand, it decreased cell survival-related proteins including
phosphatidylinositol-3-kinase (PI3K) and Akt [17], and inﬂammatory
markers including interleukin (IL)-6, cyclooxygenase-2 (COX-2), and c-
Jun [16].
With UVB models, RSV decreased bi-fold skin thickness [26,27],
hyperplasia [27], inﬁltration of leukocytes [27], and incidence [28],
and delayed the onset of tumorigenesis [28]. In addition, biomarkers
were affected by RSV treatment. Activities of ornithine decarboxylase
(ODC) [26] and COX [26] and expression levels of ODC [26], proliferating
cell nuclear antigen (PCNA) [27], cyclin-dependent kinase (CDK)2,
CDK6, and cyclinD2 [27], mitogen-activated protein kinase kinase
(MEK) [27], extracellular signal-regulated kinase (ERK) [27], survivin,
and phosphorylated (p-)survivin were downregulated. On the other
hand, the expression of p21 [27], p53 [27], and Smac/DIABLO [28] was
upregulated. Furthermore, RSV exerted the antioxidant effect with the
reduction of H2O2 and lipid peroxidation in the skin [26].
Notably, oral administration of RSV, but not topical treatment, also
resulted in positive effects, including decreases in the tumormultiplicity
[29] and volume [29], and delay in the onset of tumorigenesis [29]. The
anti-tumor effect of RSV was associated with decreased expression
levels of TGF-β1 [29] and Rictor [31], and increased expression levels
of E-cadherin [29].
With the human cutaneous skin squamous carcinoma A431 cell line
xenograft model, tumor volumewas decreased by RSV treatment, along
with increased expression levels of p53 and ERK [30], and decreased
levels of survivin [30,32]. Although ERK is considered as a proliferation
and survival protein in general, ERK was also reported to form a
complex with p53, leading to an increase in p53 phosphorylation and
expression [30]. Also, RSV enhanced the activation of caspase-3 [32].
Fig. 2.Molecular alterations resulting from RSV intervention studies with select in vivo cancer models.
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engineered animals including TLR4 deﬁcient C3H/HeJmice in theDMBA
model [19] and Sirtuin 1 (Sirt1)-null mice in the DMBA/TPAmodel [15].
Oral gavage of RSV inhibited the growth of a mouse melanoma
(B16BL6 cell line) xenograft carried in mice, with decreased expression
of Akt [33]. In another xenograft model with A2058 human melanoma
cells, intratumoral injection of RSV reduced tumor volume and this
was associated with inhibition of STAT3-DNA methyltransferase 1
(DNMT1) complex formation and the sequential decrease in the meth-
ylation of several tumor-suppressor gene (PTPN6, CDKN2A, and SOCS3)
promoters [34]. On the other hand, tumor growth of other melanoma
cell lines, including B16M [35], A375 [36], and Duke melanoma 738
xenografts in mice, was not attenuated by RSV, demonstrating limited
potential as an anti-melanoma agent [37]. Topical administration
of RSV reduced UVB-induced hyperpigmentation which is related to
melanoma formation with a decrease in tyrosinase-related protein 2
in male brownish guinea pigs (KIWA:A1) [38].
The experimental conditions and outcomes with individual animal
models are listed in Table 1.
2.2. Breast
Breast cancer is expected to be the most commonly diagnosed type
of cancer and to rank second in cancer mortality among women in the
United States in 2014, when excluding basal cell and squamous cell
skin cancers and in situ carcinoma except urinary bladder [39]. RSV
has displayed cancer chemopreventive and anti-cancer properties in
certain types of breast cancer animal models. Chemically-induced
mammary gland carcinogenesis models using DMBA [8], N-methyl-N-
nitrosourea (MNU) [40], or estradiol [41], as well as spontaneousmammary tumor models using HER-2/neu-overexpressed [42] or
Brca1-mutated (K14cre; Brca1F/F; p53F/F) mice [43], have been used to
evaluate the preventive or curative effect of RSV. Among around 20
papers found from PubMed or SciFinder searches, the DMBA-induced
model (7 publications) or xenograft in the hind ﬂank region or the
mammary fat pad (6 publications) is most commonly used.
Although some controversial studies exist indicating that RSV has no
effect [43,44] or even enhances tumorigenesis [45,46], the majority of
studies found that RSV can prevent tumorigenesis [34,40,42,47–51]. In
DMBA-induced models, dietary supplementation with RSV reduced
mammary tumor incidence associated with the alteration of biochemi-
cal markers in mammary tissue. RSV reduced the levels of lipid peroxi-
dation [4-hydroxy-2-nonenal (4-HNE)] and DNA-single-strand breaks,
inhibited the expression of COX-2, matrix metalloproteinase (MMP)-9,
5-lipoxygenase (5-LOX), nuclear factor-κB (NFκB), leukotriene B4
(LTB4; a main product of 5-LOX which can enhance proliferation and
suppress apoptosis), and cyclin D1, and attenuated the activation of
NFκB, while it increased caspase-3 activity and TGF-β1 expression in
mammary tissues of rats [52,53]. With breast cancer cell implanted fat
pad models using cigarette smoke condensate-transformed MCF-10A-
Tr cells [50] or SUM159 cells [51], RSV downregulated the expression
of cell proliferation/survival-related proteins (PI3K, β-catenin, cyclin
D1, and PCNA), DNA repair-related proteins (DNA-ligase-I, Fen-1,
Pol-δ, and Pol-ε), and anti-apoptotic protein (Bcl-xL), while it upregu-
lated tumor suppressor gene, p21, and proapoptotic protein, Bax, in
mammary tissue of mice [50,51].
Hyper-lipogenesis is a hallmark of cancer cell physiology [30]. RSV
treatment suppressed the tumor growth of cancer stem-like cells
isolated from MDAMB231Luc in a mouse xenograft model, accompa-
nied by the suppression of fatty acid synthase (FAS) which is related
Table 1
Skin cancer preventive or anti-tumor effects of RSV in animal models (the entire period).
Species (F/M1) Dose Duration Model Route Major outcome Marker Year Reference
CD-1 mice (F) 1,5,10,25 μmol With TPA, twice/week for 18 weeks DMBA/TPA Topical *Incidence↓
*Number of tumors per mouse↓
Not tested 1997 [8]
CD-1 mice (F) 1,5,10,25 μmol 30 min prior to TPA, for 4 h TPA Topical Not applicable Activities: MPO↓, GSSG reductase↓, SOD↑
Expression: c-fos↓, TGF-β1↓
H2O2↓, GSH↑
1998 [22]
ICR mice (F) 85 nmol *One week prior initiation,
*Twice/week with TPA for 20 weeks
DMBA/TPA Topical *Incidence↓
*Number of tumors per mouse↓
Not tested 2002 [12]
CD-1 mice 5,10,25 μmol Twice/week with TPA for 18 weeks DMBA/TPA Topical Incidence↓ Not tested 2002 [13]
SKH-1 mice 25 μmol Single, 30 min prior to UVB exposure UVB Topical *Bi-fold skin (dorsal and ear)
thickness↓
*Inﬁltration of leukocytes↓
Activities: ODC↓, COX↓
Expression: ODC↓
H2O2↓, lipid peroxidation↓
2003 [26]
SKH-1 mice 10 μmol 7 times, alternate days, 30 min prior
to UVB exposure
UVB Topical *Bi-fold skin thickness↓,
*Hyperplasia↓,
*Inﬁltration of leukocytes↓
Expression: PCNA↓, CDK2↓, CDK6↓,
cyclin-D2↓,
MEK↓, ERK2↓, p21↑, p53↑
2004 [27]
ICR mice (F) 1,5,25 μmol Single, 30 min prior to TPA for 4 h TPA Topical Not applicable Activities: ERK↓, p38 MAPK↓
DNA binding: AP-1↓
Expression: COX-2↓, p-ERK↓
2004 [23]
SKH-1 mice (F) 25, 50 μmol 30 min before or 5 min after UVB
exposure, twice/week for 28 weeks
UVB Topical *Incidence↓
*Onset of tumorigenesis↓
Survivin↓, p-survivin↓, smac/DIABLO↑ 2005 [28]
Swiss albino mice (M) 50 μM, 200 μL
(10 nmol)
RSV for 3 weeks→ DMBA→ TPA
(3×/week, for 24 weeks)
DMBA/TPA Topical *Incidence↓
*Onset of tumorigenesis↓
*Number of tumors per mouse↓
Bcl-2↓, p53↑, Bax↑, release of cytochrome c↑,
APAF-1↑, cleaved caspase-9,-3, and PARP↑
2008 [14]
Swiss albino mice (M) 50 μM, 200 μL
(10 nmol)
DMBA→ TPA (RSV 1 h prior to TPA,
3×/week, for 24 weeks)
DMBA/TPA Topical *Incidence↓
*Onset of tumorigenesis↓
*Number of tumors per mouse↓
*Tumor volume/mouse↓
Bcl-2↓, p53↑, Bax↑, release of cytochrome c↑,
APAF-1↑, cleaved caspase-9,-3, and PARP↑
2008 [14]
Swiss albino mice (F) 16 μmol Single, 1 h prior to BP for 24 h BP Topical Not applicable Activity:
Ethoxy-resoruﬁn dealkylase (ROD)↓,
methoxy-ROD↓, penthoxy-ROD↓, NQO1↑
2008 [18]
Swiss albino mice (F) 16 μmol Single, 1 h prior to DMBA for 24 h DMBA Topical Not applicable Activity: NQO1↓ 2008 [18]
Balb/c mice (F) 16 μmol Single, 15 min prior to TPA for 1–12 h TPA Topical Not applicable Activity: IKKβ↓, 20S proteasome↓
Expression: nuclear p65↓, IκBα↑, c-Jun↓,
COX-2↓, iNOS↓
DNA binding: c-Jun↓, p65↓, p50↓
2008 [24]
TLR4 competent C3H/HeN
mice, TLR4 deﬁcient
C3H/HeJ mice
10 μmol 1 h prior to DMBA, for 25 weeks DMBA Topical *Incidence↓
*Number of tumors per mouse↓
*Tumor volume/mouse↓
(In C3H/HeJ mice: the effects
were diminished.)
VEGF↓, MMP-2↓, MMP-9↓, IFN-γ↑, IL-12↑
(The effects were diminished in C3H/HeJ mice.)
2009 [19]
Normal (SirT1+/+ or
SirT1+/−) and
SirT1-null mice
25 μmol With TPA, once/week for
15–22 weeks
DMBA/TPA Topical *Incidence↓
*Number of tumors per mouse↓
*Tumor volume/mouse↓
(The effects were reduced but not
ablated in SirT1-null mice.)
None 2009 [15]
Swiss albino mice (F) 25, 50 μM/200 μL
(5,10 nmol)
1 h prior to DMBA, thrice/week
for 28 weeks
DMBA Topical *Incidence↓
*Number of tumors per mouse↓
*% of tumor free survival↓
*Tumor volume/mouse↓
p53↑, Bax↑, release of cytochrome c↑,
caspases activation↑, Apaf-1↑, Bcl-2↓,
PI3K↓, Akt↓ survivin↓
2009 [17]
SENCAR mice (F) 5 μmol/mouse 20 min
prior to DMBA
Twice/week, for 4 weeks DMBA Topical Epidermal thickness↓ Not signiﬁcant 2010 [21]
Highly tumor-susceptible
p53+/−/SKH-1 mice
200 mg/kg/day 3×/week for 2 weeks prior to UVB
exposure, total 27 weeks
UVB Oral gavage *Onset of tumorigenesis↓
*Number of tumors per mouse↓
*Tumor volume per mouse↓
TGF-β1↓, E-cadherin↑ 2011 [29]
p53+/−/SKH-1 mice 200 mg/kg/day 3×/week for 2 weeks prior to UVB
exposure, total 27 weeks
UVB Oral gavage Rictor↓ 2012 [31]
SENCAR mice (F) 2.5 μmol 20 min prior to DMBA DMBA/TPA Topical *Number of tumors per mouse↓ IL-6↓, c-Jun↓ 2013 [16]
SENCAR mice (F) 2.5 μmol 20 min prior to TPA, twice/week
up to 14 weeks
DMBA/TPA Topical *Epidermal proliferation↓
*Epidermal thickness↓
IL-6↓, COX-2↓, c-Jun↓ 2013 [16]
Nude mice 10, 20, 40 μg 14 days Xenograft, A431 cells i.p. Xenograft volume↓ p53↑, ERK↑, survivin↓ 2013 [30]
1 F: female, M: male.
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proapoptotic markers including death associated kinase 2 and BCL2/
adenovirus E1B 19 kDa protein interacting protein 3, which are
inhibited by FAS via ceramide synthesis, were induced by RSV [54].
In an estradiol-induced model with female ACI rats, RSV decreased
the expression level of DNMT3b, miR21, -129, -204, and -489 in tumor
but increased these factors in normal tissues [41]. Moreover, with rats,
RSV prevented mammary carcinogenesis of offspring. Gestational
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to CpG methyla-
tion of the breast cancer-1 (BRCA-1) gene and the subsequent reduction
of BRCA-1 expression in themammary tissue of offspring. Pretreatment
with RSV partially reversed the changes by upregulating the expression
of aromatic hydrocarbon receptor (AhR) repressor (AhRR) [55].
A summary of studies is given in Table 2.
2.3. Prostate
Prostate cancer is expected to be the most commonly diagnosed
type of cancer and to rank second in cancer mortality among men in
the United States in 2014, when excluding basal cell and squamous
cell skin cancers and in situ carcinoma except urinary bladder [39].
Two experimental models to evaluate the cancer chemopreventive
or anti-cancer capacity of RSV were employed primarily, including
spontaneous tumor models using genetically modiﬁed rodents or
xenograft models in which prostate cancer cells were inoculated into
the ﬂank area subcutaneously, or into the prostate.
With transgenic mouse models, dietary consumption of RSV attenu-
ated prostate tumorigenesis. For instance, with the transgenic adeno-
carcinoma mouse prostate (TRAMP) model, RSV reduced grade 4 and
6 lesions of prostatic adenocarcinoma and decreased cell proliferation
in the dorsolateral (DLP) and ventral prostate (VP) [56]. With the
transgenic rat for adenocarcinoma of prostate (TRAP) model, RSV re-
duced the content of prostatic neoplastic lesions [57,58] with inhibiting
cell proliferation in the ventral prostate [58]. With prostate-speciﬁc
phosphatase and tensin homolog (PTEN)-knockout mouse model, the
incidence of both mouse prostatic intraepithelial neoplasia (mPIN)
lesions [59] and high-grade prostatic intraepithelial neoplasia (HGPIN)
lesions [60] was reduced by RSV, with a decrease in p-S6 kinase (S6K)
and an increase of Sirt1 in prostate tissue. These results suggest that
RSV exerts an anti-tumor effect via Sirt1/S6K-mediated autophagy [60].
In xenograft models with androgen receptor (AR)-positive LNCaP
or LNCaP-Luc human prostate cancer cells, pretreatment and post-
treatment of RSV upon cell inoculation exhibited different efﬁcacies.
Treatment with RSV via the diet (6 or 12 mg/kg/day) [61] and oral
gavage (50 mg/kg/day, every other day) [62] starting 2 weeks prior to
inoculation of cells in nude mice delayed tumor growth, whereas sup-
plementation with RSV (50 mg/kg/day) in the Western diet 3 weeks
after inoculation in SCIDmice had no effect on survival [63]. In castrated
nude mice, RSV (4 g/kg diet) intervention just 1 day after implantation,
reduced tumor volume, and this was associated with a reduction of
β-catenin-mediated AR function via downregulating the expression of
hypoxia-inducible factor 1-alpha (HIF-1α) [64].
With AR-negative PC-3 human prostate cancer cell xenografts in the
ﬂank area of mice, post-treatment of oral RSV (30 mg/kg/day) reduced
tumor volumewith decreases in tumor cell proliferation and neovascu-
larization and induction of apoptosis [65].
In addition, intraperitoneal post-treatment with RSV (25 mg/kg/day)
reduced the tumor volume with PC-3 cell xenografts in the prostate of
mice [66]. However, the anti-tumor effect of RSV diminished in xeno-
grafts with sphingosine kinase-1 (SphK1)-transfected PC-3 cells, which
demonstrated that SphK1, an enzyme facilitating the conversion of the
sphingosine (proapoptotic) into S1P (prosurvival), is a target for RSV.
Also, intraperitoneal post-treatment of RSV (50mg/kg/day) in orthotopic
Du145 cell xenografts in the prostate reduced tumor growth, progression,
local invasion, and spontaneous metastasis. The effect of RSV decreased
with metastasis-associated protein 1 (MTA1)-knockdown Du145 cellxenografts indicating that MTA1 plays a crucial role in anti-tumor effect
of RSV [67].
Experimental conditions and outcomes with individual animal
models are listed in Table 3.
2.4. Lung
Lung cancer is expected to be the secondmost commonly diagnosed
type of cancer and to rank ﬁrst in cancer mortality among men and
women in the United States in 2014, when excluding basal cell and
squamous cell skin cancers and in situ carcinoma except urinary bladder
[39]. In animal models, a variety of agents are known to induce lung
carcinogenesis, including nitrosamine 4-(methyl-nitrosamino)-1-(3-
pyridyl)-1-butanone (NNK), diethylnitrosamine (DEN), BP, vinyl carba-
mate, uracil mustard, urethane, and MNU [11]. Using BP plus NNK [69]
or BP only [70] in mouse models, RSV supplemented in the diet had
no effect on lung tumor multiplicity [69], the expression levels of
CYP1A1 and CYP1B1 [70], or the level of BP protein adduct [70]. On
the other hand, RSV treatment in the BP-induced mouse lung carcino-
genesis model reduced the level of BP diolepoxide (BPDE)-DNA adduct
[71], improved ultrahistoarchitecture [72], decreased the development
of tumor nodules with increased pulmonary caspase-3 and -9 activities,
and decreased glucose uptake/turnover and serum lactate dehydroge-
nase (LDH) activity (It is elevated in cancer cells involving cancer cell
metabolism) and p-p53 levels at Ser15 (Its hyperphosphorylation can
lead to the inactivation of p53) [73].
With Lewis lung carcinoma cell xenograft models, RSV treatment at-
tenuated tumor growth [74–77], and this was associatedwith increased
apoptosis accompanied by elevated TUNEL-positive cells [75,76]
and caspase-3 activity [75] and reduced angiogenesis-related protein,
factor VIII [75] in tumors, and decreased oxidative stress along with an
increase in superoxide dismutase (SOD) activity and a decrease in
malondialdehyde (MDA) content in serum [77].
Over the past 5 years, it has been found that RSV treatment attenu-
ated the growth of A549 [78,79] and MSTO-211H [80] xenografts in
mice. Several biochemical/molecular alterations occurred with RSV ad-
ministration: RSV suppressed tumor ﬂuorodeoxyglucose (18F-FDG) up-
take (amarker for the tissue uptake of glucose) in Lewis lung carcinoma
xenograft mice [81], increased cleavage of caspase-3 (apoptosis mark-
er), and reduced speciﬁcity protein 1 (Sp1; highly expressed in various
cancers) in MSTO-211H-bearing mice [80]. Forkhead box protein
C2 (FOXC2) was reported to enhance tumor metastasis and induce
epithelial to mesenchymal transition (EMT). One study with mice
demonstrated that the anti-tumor effect of RSV in A549 xenografts
was diminished in FOXC2—overexpressing A549 xenografts, suggesting
that RSV possibly exerts anti-tumor activity via FOXC2 [79].
The experimental conditions and outcomes with individual animal
models are listed in Table 4.
2.5. Colon
Colorectal cancer is expected to be the third most commonly di-
agnosed type of cancer and rank third in cancer mortality among
men and women in the United States in 2014, when excluding
basal cell and squamous cell skin cancers and in situ carcinoma ex-
cept urinary bladder [39]. In addition to using genetically modiﬁed
animals such as ApcMin/+ mice and ApcPirc/+ rats, chemical carcino-
gens induce colon cancer, including azoxymethane (AOM), AOM
plus dextran sulfate sodium (DSS), 2-amino-3-methylimidazo[4,5-
f]quinoline, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine,
and 1,2-dimethylhydrazine (DMH) [10,11,82]. The histopathological
and pathophysiological manifestations/features of colon cancers can
be observed, including hyperplasia, aberrant crypt foci (ACF), adeno-
ma, and adenocarcinoma [82].
In AOM- or AOM plus DSS-induced models, oral administration (in
the diet or gavage) of RSV reduced the incidence [83,84], multiplicity
Table 2
Breast cancer preventive or anti-tumor effects of RSV in animal models (the entire period).
Species (F/M1) Dose Duration Model Route Major outcome Marker Year Reference
Sprague–Dawley rats (F) 10 and 100 mg/kg/day 5 days/week, 1 week before
MNU injection, for ~17 weeks
MNU Oral gavage *Incidence↓
*Number of tumor/rat↓
Not available 2001 [40]
Sprague–Dawley rats (F) 100 μg/rat/day 1 week before DMBA, for 127
days
DMBA In diet *No effect on tumor volume
*Incidence↓
*Multiplicity↓
*Latency period of tumor
development↑
COX-2↓, MMP-9↓,
NFκB activation↓
2002 [52]
FVB/N HER-2/neumice (F) 4 μg/mouse/day Starting from week 20,
for ~2 months
Spontaneous mammary
tumor
In drinking
water
*Onset of tumorigenesis↓
*Tumor volume↓
*Multiplicity↓
HER-2/neu (mRNA)↓ 2005 [42]
Sprague–Dawley CD rats (F) 50, 100 mg/kg/day Whole life time DMBA In diet *Multiplicity↓
*Latency period of tumor
development↑
*Differentiated lobular structures
of mammary glands↑
*Proliferative cells in mammary
terminal ductal structures↓
Not available 2006 [47]
Athymic mice (F) 25 mg/kg/day Daily after tumor size reached
40 mm3 for 3 weeks
Xenograft with
MDA-MB-231 cells
i.p. *Tumor volume↓
*TUNEL staining↓
*Microvessel density↓
Not available 2006 [48]
Sprague–Dawley rats (F) 0.2 mg/kg/day Daily, for ~14 weeks
(from 40 days until
20 weeks of age)
DMBA Oral gavage *Number of 8-OHdG and 8-isoPGF2α
contents in tumors↓
*Incidence↓
Protein carbonyl
(Oxidized protein)↓
2009 [49]
Sprague–Dawley rats (F) 100 μg/rat/day 19 weeks DMBA In diet *Lipid peroxidation↓
*DNA damage↓
*Cell proliferation↓
*Apoptosis↑
Activity: Caspase-3↑
Expression: 5-LOX↓,
TGF-β1↑, NFκB p65↓,
LTB4↓
2011 [53]
Athymic nude mice 25 mg/kg/day,
twice/week
starting when tumor
volume reached ∼150
mm3
Day 7–26 (20 days) Xenograft, MDA-MB468
cells
i.p. Tumor volume↓ Not available 2012 [34]
Balb/c mice (F) 40 mg/kg/day 30 days Xenograft in mammary fat
pad with cigarette smoke
condensate-transformed,
MCF-10A-Tr cells
Oral gavage Tumor volume↓ p21↑, PI3K↓, NFκB↓,
Bcl-xL↓, cleaved PARP
↑,
BAX↑, PCNA↓, Fen-1↓,
Pol-δ↓, Pol-ε↓, H2AX↑
2014 [50]
Nonobese diabetic/severe
combined
immunodeﬁcient
mice (NOD/SCID) (F)
100 mg/kg/d, daily 14 days Xenograft in mammary
fat pads with SUM159 cells
i.v. *Tumor growth↓
*breast cancer stem cell population in tumor
cells↓
*Aldehyde dehydrogenase-positive
populations in tumor cells↓
β-Catenin↓, cyclin D1
↓
2014 [51]
1 F: female, M: male.
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Table 3
Prostate cancer preventive or anti-tumor effects of RSV in animal models (the entire period).
Species (F/M1) Dose Duration Model Route Outcome Marker Year Reference
Heterozygous
TRAMP (M)
625 mg/kg diet 7 or 23 weeks Spontaneous prostate
tumor
In diet *Incidence of poorly differentiated
prostatic adenocarcinoma
(Grade 6 lesions)↓
*Progression of well differentiated
(Grade 4 lesions)↓
Dorsolateral prostate (DLP):
Androgen receptor (AR)↑, ER-β↑,
IGF-1↓, IGF-1R↑, p-ERK1↓
Ventral prostate (VP):
IGF-1R↓, p-ERK1↓ p-ERK2↓
2007 [56]
Heterozygous
TRAP rats (M)
7.6, 16.1, or
30.1 mg/kg/day
7 weeks Spontaneous prostate
tumor
Drinking
water
*Serum testosterone↓ (not 200 μg/mL)
*Prostatic neoplastic lesions↓
*Numbers of apoptotic cells↑
*No signiﬁcant differences in the
incidences of PIN or adenocarcinoma
*No difference in Ki-67
Serum: testosterone↓
Ventral prostate: AR↓, androgen
responsive gene, Gk11↓
2008 [57]
Athymic nude mice
(Balb/cAnNCr-nu/nu)
(M)
6 or 12 mg/kg/day Starting 2 weeks before
implantation, total
9 weeks
Xenograft, LNCaP cells In diet *Tumor growth↓
*Apoptosis↓
*Microvessel formation↑
(PECAM-1 staining↑)
Prostate-speciﬁc antigen (PSA)↓ 2008 [61]
Homozygous PTEN
knockout mice (M)
50 mg/kg/day 3 times a week,
total 7 weeks
Spontaneous prostate
tumor
Oral gavage *The mean genitourinary
tract and prostate weights↓
*The incidence of mouse prostatic
intraepithelial neoplasia (mPIN) lesions↓
*Regression of adenocarcinomas↓
Not available 2009 [59]
TRAP rats (M) 15 mg/kg/day 30 weeks Spontaneous prostate
tumor
In diet *Incidence (Grades 4–6)↓
*21% prostate cancer free (CTL: 2% free)
*Cell proliferation in the VP↓ (not DLP)
*Apoptosis in the VP↑
Ventral prostate:
IGF-1↓, AR↑
2009 [58]
Athymic nude mice
(Balb/c nu/nu)
30 mg/kg/day Thrice/week, beginning
when tumor volume
reached about 100 mm3,
total 6 weeks
Xenograft, PC-3 cells Oral gavage *Tumor volume↓
*Cell proliferation↓
*Apoptosis↑
*Number of blood vessels↓
PCNA↓, Ki67↓, death receptor
(DR4)↑, DR5↑, Bax↑, Bcl-2↓, p27↑,
cyclin D1↓, MMP-2↓, MMP-9↓, CD31↓,
von Willebrand Factor↓, VEGF↓,
circulating VEGF-R2↓, p-FOXO3a↓,
FOXO3a-DNA binding activity↑
2010 [65]
NMRI/Nu (nu/nu)
mice (M)
25 mg/kg/day Daily, 10 days after implantation,
total 2 weeks
Intraprostatic xenograft,
PC-3, PC-3/neo, or
PC-3/SphK1 cells
i.p. *Tumor volume↓ (no effect with
PC-3/SphK1 cells)
SphK1 activity↓, ceramide↑, S1P↓ 2010 [66]
SCID mice (M) 20 mg/kg/day Alternate days, starting 1 week
before implantation until the
end of the study, total 39 days
Xenograft, PC-3 M-MM2
(highly invasive) cells
Oral gavage *Tumor volume↓
*Tumor weight↓
miR-21↓, Akt↓, programmed
cell death 4↑
2012 [68]
PTEN knockout mice 0.1% and 2% in diet 14 weeks Spontaneous prostate
tumor
In diet *Prostate weight↓
*Incidence of high-grade prostatic
intraepithelial neoplastic (HGPIN)↓
Prostate:
mTOR complex 1 activity↓
Sirt1 expression↑
2013 [60]
Nude mice (M) 50 mg/day 2 weeks after implantation,
total 42 days
Xenograft, CWR22 cells Osmotic mini
pump, s.c.
No effect compared with controls Cyclin D1↓ 2013 [37]
Nude mice Alternate days, starting
2 weeks before implantation,
total 7 weeks
Xenograft, LNCaP-Luc cells Gavage Tumor growth↓ Not available 2013 [62]
SCID mice 50 or 100 mg/kg/day 3 weeks after injection,
total ~150 days
Xenograft, LAPC-4 cells In Western
diet
*Survival in 50 mg/kg/day
(not 100 mg/kg/day)↑
*IGF-1/IGFBP-3 ratio
(a measure of free IGF-1)↓
Insulin↓, IGF-1↓,
E2F3 pathway↑, β-catenin pathway↑
2013 [63]
SCID mice 50 mg/kg/day 3 weeks after implantation,
total ~150 days
Xenograft, LNCaP cells In Western
diet
No effect on survival IGFBP-2↑ 2013 [63]
Nude mice (M) 50 mg/kg/day Daily, 14 days after implantation,
total 6 weeks
Xenograft in anterior
prostate, Du145-EV-Luc or
Du145-MTA1shRNA-Luc
i.p. In Du145-EV-Luc:
*Tumor growth↓
*Progression, local invasion↓
*Spontaneous metastasis↓
*Angiogenesis↓
*Apoptosis↑
Ki-67↓, p53 acetylation↑,
M30 (apoptosis)↑
CD31 (microvessel)↓
2013 [67]
Balb/cSlc-nu/nu
castrated mice (M)
4 g/kg diet 1 day after implantation,
total 40 days
Xenografts, LNCaP cells In diet *Tumor volume/weight↓ HIF-1α↓, hypoxia-responsive
genes (VEGF, PSA)↓
cytosolic β-catenin↑
2014 [64]
1 F: female, M: male.
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alteration of biomarkers. RSV increased the expression of Bax [85],
p53 and p-p53 at Ser15 [83], heme oxygenase-1 (HO-1) [86], glutathi-
one reductase (GR) [86], and nuclear localized nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) [86], whereas it decreased the
expression of inducible nitric oxide synthase (iNOS) [83,86], COX-2
[83,86], tumor necrosis factor alpha (TNF-α) [83], aldose reductase
[86], NFκB [86], and p-protein kinase C-β2 (PKC-β2) [86]. It is suggested
that RSV down-regulated aldose reductase-dependent activation of
PKC-β2 and NFκB, with a subsequent decrease in the expression level
of iNOS and COX-2 [86].
In DMH-induced models, RSV reduced the incidence [87], multiplic-
ity [87–89], size [87,88] of ACF, histopathological lesions [87], and DNA
damage in leukocytes [90]. The anti-tumor effect of RSV against colon
carcinogenesis is accompanied by the alteration of enzyme activities:
In rat models, the activities of antioxidant enzymes including SOD and
catalase (CAT) in the intestine/colon [88], liver [91], and erythrocytes
[90] were increased, while the activities of biotransforming enzymes
including β-glucuronidase, β-glucosidase, β-galactosidase, mucinase,
and nitroreductase in colonic mucosal and fresh fecal samples were
decreased [87]. In addition, the expression levels which are altered by
DMH in rats were normalized by RSV treatment: RSV reduced the ex-
pression levels of COX-2, ornithine decarboxylase (ODC), heat shock
protein (Hsp)27, Hsp70, and MUC1 in colonic mucosa [92], and
β-catenin in ACF [93], whereas it induced the expression levels of
caspase-3 in colonic mucosa [92] and glutathione, reduced state
(GSH), in the intestine/colon [88], liver [91], erythrocytes [90], and plas-
ma [90]. With genetically modiﬁed mouse models (e.g. ApcMin/+ mice
[94–96], and mice with APC locus knockout and activated Kras [97]),
supplementation with RSV inhibited the formation of colon tumors
[94–97] and dysplasia occurrence [96]. At the mRNA level, RSV down-
regulated i) cell survival-related mRNA (cyclins D1 and D2, DP-1
transcription factor, and Y-box DNA-binding protein), and upregulated
ii) recruitment and activation of immune cell-related mRNAs
(cytotoxic T lymphocyte Ag-4, leukemia inhibitory factor receptor, and
monocyte chemotactic protein 3), and iii) carcinogenic process and
tumor expansion-related mRNA (tumor susceptibility protein TSG101,
TGFβ, inhibin-βA subunit, and desmocollin 2) in small intestinal mucosa
[94]. At the miRNA level, RSV induced the expression of miR-96, which
regulates Kras translation [97]. In addition, RSV reduced levels of PGE2
in the intestine [95].
The experimental conditions and outcomes with individual animal
models are listed in Table 5.
2.6. Liver
Hepatocarcinogenesis can be induced byDEN,DENplus phenobarbi-
tal, aﬂatoxin, CCl4, thioacetamide, peroxisome proliferators, and a
choline deﬁcient diet in animal models. Also, it can be observed in
genetically engineered models including hepatitis virus transgenic and
Mdr2 knockout models [99]. RSV treatment, either at early or advanced
stages of hepatocarcinogenesis, has been shown to be effective. The
experimental conditions and outcomes with individual animal models
are listed in Table 6.
From the late 1990s, the chemopreventive effects of RSV on liver
carcinogenesis with decreased incidence [100,101] and nodules
number [100,101] in animal models using chemical inducers
[e.g., DEN [101–104], DEN plus phenobarbital [100], and DEN plus
2-acetylaminoﬂuorene (2-AAF)] [105] or using transgenic mice
[e.g., hepatitis B virus X protein (HBV X)-expressing transgenic
mouse] [106], as well as the anti-tumor effects of RSV on xenograft
models with hepatoma cell lines (e.g., AH-130 [107], H22 [108,109],
AH109A [110], Bel-7402 [111], and HepG2 [112]) have been reported.
The majority of studies showed that RSV reduced total tumor cell
number [107], tumor growth [108,109], tumor weight [110], and
angiogenesis/microvessel density [113] with rodent hepatoma
Table 5
Colon cancer preventive or anti-tumor effects of RSV (the entire period).
Species (F/M1) Dose Duration Model Route Outcome Marker Year Reference
F344 rats (M) 200 μg/kg/day Starting at 10 days before AOM treatment,
total 100 days
AOM In drinking water *Number of ACF/colon↓
*Large ACF↓
ACF:
Bax↑
2000 [85]
C57BL/6J ApcMin
mice (M)
0.01% in drinking
water (0.3–0.4 mg/kg/day)
From 5-week-old, total 7 weeks Spontaneous
tumor model
In drinking water Colon and small intestinal tumors↓ Small intestinal mucosa:
*Cyclins D1 and D2↓, DP-1 transcription
factor↓, Y-box DNA-binding protein↓
*Cytotoxic T lymphocyte Ag-4↑, leukemia inhibitory
factor receptor↑,monocyte chemotactic
protein 3↑
*Tumor susceptibility protein TSG101↑,
TGFβ↓, inhibin-βA subunit↑, desmocollin 2↑
2001 [94]
C57BL/6J ApcMin/+
mice (M)
4, 20, or 90 mg/kg/day From 43-day-old, total 7 weeks Spontaneous
tumor model
In diet No effect on intestinal tumor load
in the small or large intestine
*No changes in COX-2 expression
*PGE2 levels of small intestinal tumors↓
2004 [98]
C57BL/6J
ApcMin/+(M)
0.05% or 0.2% in the diet
(60 and 240 mg/kg/day)
From 4-week-old, total 3 weeks Spontaneous
tumor model
In diet Adenoma load↓ PGE2 levels in the intestinal mucosa↓ 2005 [95]
Wistar rats (M) 8 mg/kg/day Daily, starting on the day of DMH injections till
the end of study (the entire period), total 30 weeks
DMH Oral *Multiplicity, size, total number of ACF↓ Intestine and colon:
Levels: Diene conjugates↑, lipid hydroperoxides↑,
TBARS↑, GSH↑, vitamin C↓ α-tocopherol↓
Activity: SOD↑, CAT↑, GPx↓, GST↓, GR↑
2006 [88]
Wistar rats (M) 8 mg/kg/day Daily, starting on the day of DMH injections
till the end of study (the entire period),
total 30 weeks
DMH Oral gavage *Incidence↓, *Tumor volume↓, *Tumor
burden/rat↓
*Histopathological lesions DMH↓
Colonic mucosal and fresh fecal samples:
Activity: β-Glucuronidase↓,
β-glucosidase↓, β-galactosidase↓, mucinase↓,
nitroreductase↓
Fresh fecal samples:
sulfatase activity↓
2006 [87]
Wistar rats (M) 8 mg/kg/day Daily, starting on the day of DMH injections till
the end of study (the entire period), total 30weeks
DMH Oral gavage *Number of argyrophilic
nucleolar organizing region-associated
proteins (AgNORs) per nucleus↓
Liver:
SOD↑, CAT↑, GSH↑, TBARS↓
2006 [91]
Wistar rats (M) 8 mg/kg/day Daily, starting on the day of DMH injections till
the end of study (the entire period), total 30weeks
DMH Oral gavage Not available Colonic mucosa:
COX-2↓, ODC↓, Hsp27↓, Hsp70↓, Caspase-3↑, MUC1↓
2009 [92]
Wistar rats (M) 4, 8, or
12 mg/kg/day
Daily, starting on the day of DMH injections
till the end of study (the entire period),
total 2 weeks for DNA damage study,
total 30 weeks for oxidative stress
DMH Oral gavage DNA damage in the leukocyte↓ Plasma:
TBARS↓, GSH↑, TRAP↑, vitamins C and E↑, β-carotene↑
Erythrocyte:
Levels: GSH↑
Activity: SOD↑, CAT↑, GR↑, GPx↑, GST↑
2009 [90]
C57BL/6 mice
(M/F)
300 ppm in diet
(48 mg/kg/day)
62 days AOM/DSS In diet *Colon tumor incidence↓
*Number of tumors/animal (multiplicity)↓
*Neutrophil inﬁltration [Number of
neutrophils in mesenteric lymph
nodes (MLN) and lamina propria (LP) sites]↓
Colon:
iNOS↓, COX-2↓, TNF-α↓, p53↑, p-p53 (Ser15)↑
T cells in MLN and LP:
*TNF-α↓, IFN-γ↓
2010 [83]
Sprague–Dawley
rats (M)
60 mg/kg/day 49 days DMH Oral *ACF↓
*Mucin depleted foci↓
Not available 2010 [89]
Balb/c mice (M) 50 or 250 ppm Twice/week for 2 weeks (total 4 times)
along with RSV 50, or 250 ppm in diet→ RSV
diet for 22 weeks, total 6 or 24 weeks
AOM In diet *Total number of aberrant crypt foci
(ACF) and aberrant
crypts (AC)↓
*Lymphoid nodule (LN) numbers↓
Colonic mucosa:
6 weeks after the ﬁrst AOM injection
iNOS↓, COX-2↓, aldose reductase↓, HO-1↑, GR↑
12 weeks after the ﬁrst AOM injection
iNOS↓, COX-2↓, p-PKCβ2↓, and p-p65↓
Colonic ACF:
Expression and nuclear localization of Nrf2↑,
aldose reductase↓
2011 [86]
Wistar rats (M) 10, or 20 mg/kg/day After induction of cancer, total 10 weeks EDTA/DMH Oral Not available β-Catenin in ACF↓ 2012 [93]
Wistar rats (M) 2 g/kg diet 2 weeks after the last AOM, total 7 weeks AOM In diet *ACF incidence↓
*Inﬂammation
and oxidation-related metabolites↓
*Mitochondrial disruption↓
*Reversal of altered metabolites↑
Colonic tissue:
Glucose↑, β-hydroxybutyrate (ketone body)↑,
hypoxanthine↑, branched chain amino acids
(isoleucine and valine)↓, tryptophan↓
Serum:
Aminooxyacetate↓
Urine:
4-Hydroxyphenylacetate↓, xanthurenate↓
2012 [84]
ApcMin mice (M) 45 μg/kg/day From 6-week-old, co-administration with BP,
total 60 days
BP Oral gavage *Number of colon adenomas↓
*Dysplasia occurrence↓
Not available 2013 [96]
1 F: female, M: male.
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Table 6
Liver cancer preventive or anti-tumor effects of RSV in animal models (the entire period).
Species (F/M1) Dose Duration Model Route Outcome Marker Year Reference
Wistar rats (M) 1 mg/kg/day Daily, 7 days Xenograft, AH-130 cells i.p. *No effect on tumor volume
*Total tumor cell number↓
*Cells in G2/M phase↑
Not available 1999 [107]
Balb/c mice 500, 1000,
1500 mg/kg/10 day
Starting on 2nd day after
implantation, 10 days
Xenograft, H22 cells i.p. Tumor growth↓ Not available 2003 [108]
Balb/c mice 5, 10 or
15 mg/kg/day
Starting 24 h after
implantation, 10 days
Xenograft, H22 cells i.p. Tumor growth↓ Cyclin B1↓, p34cdc2↓ 2003 [109]
Donryu rats (M) 10, 50 ppm 20 days Xenograft, AH109A cells In diet RSV showed trends, but not signiﬁcant.
*Tumor weigh↓
*Metastasis↓
*Excretion of neutral sterols and bile acids into feces↑
Serum:
TBARS↓, triglyceride↓
(VLDL + LDL)-cholesterol↓
2003 [110]
Pathogen-free
Sprague–
Dawley rats (F)
50, 100 or
300 mg/kg/day
Starting 4 weeks prior to
initiation, total 24 weeks
DEN/phenobarbital In diet *Incidence↓
*Total number and multiplicity of visible
hepatocyte nodules↓
*Mean nodular volume and nodular volume as
percentage of liver volume↓
*Cell proliferation↓
*Apoptotic cells↑
Bax↑, Bcl-2↓ 2009 [100]
Balb/c-nu
nude mice (F)
15 mg/kg/day Daily, starting at day 10
after tumor cell inoculation,
total 21 days
Xenograft, HepG2 cells with
different stable transfectants
(none, He-CAV1, He-CAVM1,
He-CAVM2, He-GFP and
He-CAVRNAi)
i.p. *Tumor growth in HepG2 cells (wild type or
expressing one of the various mutant constructs)↓
with more dominant in xenografts of HepG2 cells
stably expressing CAV1
Not available 2009 [112]
Sprague–Dawley
rats (F)
50, 100 or
300 mg/kg/day
Starting 4 weeks prior to
initiation, total 24 weeks
DEN/phenobarbital In diet Not available HSP70↓, COX-2↓ nuclear NFκB↓
cytosolic IκB↑
2010 [114]
Sprague–Dawley
rats (F)
50, 100 or
300 mg/kg/day
Starting 4 weeks prior to
initiation, total 24 weeks
DEN/phenobarbital In diet *Oxidative stress and inﬂammatory markers↓ Liver:
TBARS↓, protein carbonyls↓, iNOS↓,
3-nitrotyrosine↓, Nrf2↑
2010 [103]
Sprague–Dawley
rats (F)
50, 100 or
300 mg/kg/day
Starting 4 weeks before
initiation, total 18 weeks
DEN/phenobarbital In diet *Nodule incidence↓
*hepatic tumor multiplicity↓
RSV did not exhibit any cardiotoxicity but rather
improved the cardiac function.
Not available 2011 [101]
Wistar rats (M) 20 mg/kg body
weight
Daily, for 15 days
*Pre-treatment: From
day 1 of DEN injection
*Post-treatment: After the
development of carcinoma
DEN/phenobarbital Oral *Total liver mass↓
*Body mass↑
Serum:
α-fetoprotein↓
Liver and serum:
ALP↓, ACP↓, 5′ND↓, γ-GT↓, LDH↓
Liver: PARP cleavage↑, caspase-3 activation↑,
p53↑, cytochrome c release↑, Bax↑ Bcl2↓
2011 [104]
HBV X protein (HBx)
transgenic mice
30 mg/kg/day Daily, from 4-week-old HBx Oral
gavage
*Onset of tumor↓
*HCC incidence↓
Expression: LXRα↓, Srebp1-c↓, PPARγ↓,
ACC↓, Fas↓
Activity: Ampk↑, Sirt1↑
2012 [106]
SD rats (M) 60 mg/kg/day Daily, 2 week after DEN
injection, total 6 weeks
DEN/2-AAF Oral
gavage
*Area and number of GST-P-positive foci
(a marker of hepatocarcinogenesis)↓
*Expression of GST-P and Cyp2e1 in both foci
and surrounding liver tissue↓
Liver (GST-P-positive foci and surrounding
liver tissue):
Cyp2e1↓, GST-P↓
Whole liver:
Cyp1a1↓, Cyp1a2↓, Cyp2b1↓
2013 [105]
1 F: female, M: male.
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ing cyclin B1 and p34cdc2 [109], inﬂammatory IL-8 [111], and
angiogenesis-related vascular endothelial growth factor (VEGF) [113],
and an increase in the excretion of neutral sterols and bile acids into
feces [110].
With chemically induced carcinogenesis models, RSV exerted apo-
ptotic effects accompanied by the induction of proapoptotic markers
(expression of Bax [100,104] and p53 [104], PARP cleavage [104],
caspase-3 activation [104], cytochrome-c release [104]) and antioxi-
dant/detoxiﬁcation regulator (Nrf2) [103]. On the other hand, RSV re-
duced an anti-apoptotic marker in the liver (expression of Bcl-2 [100,
104]), inﬂammatory proteins in the liver (Hsp70 [114], COX-2 [114], nu-
clear NFκB [114], cytosolic inhibitor of kappa B (IκB) [114], TNF-α [102],
IL-1β [102], IL-6 [102], and iNOS [103]), oxidative stress markers in the
liver [thiobarbituric acid reactive substances (TBARS), protein carbonyls,
3-nitrotyrosine, and iNOS] [103], and other factors both in the liver and
serum [alkaline phosphatase (ALP), acid phosphatase (ACP), 5′-nucleo-
tidase (5′ND), γ-glutamyl transpeptidase (γ-GT), and LDH] [104], and a
serummarker for liver cancer (α-fetoprotein) [104].
In the spontaneously induced hepatocellular carcinoma in HBV X-
associated transgenic mice, RSV inhibited intracellular reactive oxygen
species (ROS) and hepatic lipogenesis with the down-regulation of
liver X receptor-α, sterol regulatory binding protein-1c, acetyl-CoA
carboxylase (ACC), FAS and peroxisome proliferator-activated receptor
γ (PPARγ). The expression of energy metabolism related proteins
including 5′ AMP-activated protein kinase (AMPK) and Sirt1 was en-
hanced [106].
2.7. Other cancers in recent years (2009–2014)
High levels of post-translational modiﬁcation with O-linked β-N-
acetylglucosamine (O-GlcNAc) moieties are a manifestation of tumor
progression, and one feature of chronic lymphocytic leukemia cells
[115]. RSV treatment increased survival rate and reduced tumor burden
with decreased spleen weight and high levels of O-GlcNAc (a marker of
tumor progression) proteins in the spleen of both friend murine
leukemia virus- or CB3 cell line-engrafted mouse erythroleukemias
[115]. RSV could prolong the lifespan of mice engrafted with acute
myeloblastic leukemia cells Kasumi-1, with the attenuation of signal
transducer and activator of transcription 3 (STAT3) phosphorylation
[116]. However, intraperitoneal or dietary RSV did not attenuate the
progression of high risk human acute lymphoblastic leukemia with
translocation t(4;11) [t(4;11) ALL] in mice engrafted with t(4;11) ALL
cells [54,60].
RSV application prevented the incidence and growth of oral
preneoplastic lesions and oral squamous cell carcinoma in DMBA-
induced oral carcinogenesis in the hamster cheek pouch [117]. RSV
treatment reduced tumor growth of human nasopharyngeal carcinoma
cells (CNE-2Z cell line) [118], head and neck cancer-derived tumor-
initiating cells (HNC-TICs) [119], and head and neck squamous cell
carcinoma (HNSCC) cells (FaDu cell line) [120], in nude mouse xeno-
graft models. With the anti-tumor effect of against head and neck can-
cer, RSV suppressed tumor stemness by reducing the expression of
stemness markers (Oct4 and Nestin) and mesenchymal-like protein
(Vimentin), and induced epithelial protein (E-cadherin) [119], in-
creased cleaved caspase-3 (an apoptotic marker) and γ-histone 2AX
(a DNA damage marker) [120].
RSV exerted anti-tumor and anti-angiogenic effects with decreases
in microvessel density, plasma VEGF and intra-tumoral receptor type-
2 (KDR/fetal liver kinase 1) levels with Ehrlich ascites carcinoma-
bearing mice [121]. Intravesical instillation or RSV attenuated tumor
growth with an increase in the expression of Sirt1 and p53, and a de-
crease in the expression of STAT3, p-STAT3, c-Myc, cyclin D1, survivin,
and VEGF, in the orthotopic bladder transitional cell carcinoma (TCC)
nude mouse model [122]. RSV inhibited tumor growth with a decrease
in the expression of Ki67, cyclin D1, CDK4, and CDK6, and an increase inthe expression of p21, p16, and β-Gal (a speciﬁcmarker formammalian
senescent cells) in a gastric cancer xenograft nude mice model. The de-
pletion of Sirt1 abolished the anti-tumor effect of RSV, demonstrating
the involvement of Sirt1 in RSV action [123].
The forkhead transcription factors of theO class (FOXO) are involved
in oxidative stress signaling, proliferation, and tumorigenesis. RSV sup-
pressed the tumor growth of PANC-1 cells orthotopically implanted in
nude mice with increased apoptosis/cell cycle arrest proteins
including Bim, cleaved caspase-3, and p27, and decreased cell
survival/proliferation markers including the expression of PCNA
and phosphorylation of ERK, PI3K, Akt, p-FOXO1 (Ser256), and
FOXO3a (Ser253) [124]. However, RSV did not show an anti-tumor
effect with NuTu-19 ovarian cancers in rats [125], and one study
demonstrated that RSV treatment did not affect tumor growth in
the CWR22 xenograft model [37].2.8. Metastasis
Oral treatment of RSV via gavage or diet (0.1–1 mg/kg body
weight/day) exhibited anti-metastatic effects with melanoma [33,
126] or breast cancer cells [127] in mouse models. In a hepatic mel-
anoma model with B16M cells, IL-18 is mainly involved in metasta-
ses. Oral treatment with RSV inhibited metastatic growth,
decreased metastatic foci and metastatic volume in the liver of
intrasplenically injected B16M cells, with a decrease in proinﬂam-
matory IL-18 levels in hepatic blood [126]. Oral treatment with RSV
reduced lung metastasis (decreased tumor volumes) of melanoma
cells (B16BL6 cells) with the down-regulation of Akt expression [33].
RSV inhibited cancer metastasis with a decrease in the number of
pulmonary nodules and plasma MMP-9 activity with 4T1 mouse
breast cancer cell line-injected mice [127].
In addition, in vitro treatment with RSV or via the intraperitoneal
route resulted in suppression of metastasis. EMT has been linked tome-
tastasis. Incubation with RSV inhibited LPS-induced EMT of K1735 mel-
anoma cells in vitro, resulting in prolonged animal survival and reduced
lung metastasis after tail vein injection of LPS-exposed K1735 cells in
mice [128]. Intraperitoneal injection of RSV inhibited lung metastasis
of A549/VC mice with a reduced number of colonies in the lung while
the inhibitory effect was diminished in A549/FOXC2-injectedmice, sug-
gesting that FOXC2 is critical for RSV-mediated suppression of tumor
metastasis [79].3. Inﬂammatory diseases
Over the past ﬁve years, studies involving RSV treatment in rodent
models of inﬂammatory diseases have demonstrated downregulation
of inﬂammation-induced biomarkers including proinﬂammatory medi-
ators [e.g., IL-1β, -6, and -23p19, TNF-α, monocyte chemoattractant
protein-1 (MCP-1), IFN-γ, NFκB, COX-2, iNOS, and prostaglandin E
synthase-1 (PGES-1)], oxidative stress markers [e.g., MDA, nitric oxide
(NO)], and endogenous vasoconstrictors (e.g., angiotensin II, and
endothelin), and upregulation of inﬂammation-reduced biomarkers in-
cluding anti-oxidant protein (e.g., SOD) and anti-inﬂammatory protein
(e.g., IL-10).
RSV treatment attenuated histopathologic changes (saponiﬁcation
spots in the intraperitoneal cavity, severe pancreatic edema, hemor-
rhage, necrosis, etc.) as well as elevated biochemical markers in blood
plasma (renin activity and levels of angiotensin II, endothelin, and
NO) in taurocholate-induced severe acute pancreatitis (SAP) in rats
[129].
RSV reversed the decrease in SOD levels and the increase in MDA in
intestine tissue. Also, RSV reversed the increase of TNF-α levels in
serum. RSV prevented injury to the intestinal barrier in the rat SAP
model [130].
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β1) and the histologic ﬁbrosis score in cecal tissue of peptidoglycan-
polysaccharide-injected rats (animal model for Crohn's disease) [131].
RSV reduced cartilage destruction, the loss of matrix proteoglycan
content in cartilagewith a decrease in the apoptosis rate of chondrocyte
and the level of NO in the synovial ﬂuid in experimental osteoarthritis
with rabbits [132].
RSV treatment 1) extended survival with increased numbers of
regulatory T cells and intestinal epithelial cell proliferation/
regeneration in the ileummucosa, 2) decreasedmucosal T lymphocyte
and neutrophilic granulocyte numbers, 3) presented fewer proinﬂam-
matory enterobacteria and enterococci and higher anti-inﬂammatory
lactobacilli and biﬁdobacteria loads, and 4) maintained intestinal barri-
er functions in amurinemodel of hyper-acute Th1-type ileitis following
peroral infectionwith Toxoplasma gondii. This anti-inﬂammatory action
accompanied an increase in anti-inﬂammatory cytokine IL-10 in ileum,
mesenteric lymphnodes and spleen, and a decrease in proinﬂammatory
cytokine expression (IL-6, IL-23p19, IFN-γ, TNF-α, and MCP-1) in the
ileum [133].
With chronic DSS-induced colitis in mice, RSV treatment resulted in
a higher survival than control with reduced clinical symptoms including
loss of bodyweight, diarrhea and rectal bleeding, and improved the dis-
ease activity index and inﬂammatory score. The anti-inﬂammatory ef-
fect of RSV was concomitant with decreased levels of TNF-α, IL-1β,
PGES-1, COX-2 and iNOS, and p-p38, and increased levels of IL-10 [134].
RSV treatment abrogated an increase in vascular permeability
(increased peritoneal lavage) and neutrophil migration (in peritoneum)
associated with a decreased release of serum IL-1β, IL-6, TNF-α, and
macrophage inﬂammatory protein 1α (MIP)-1α in the C5 anaphylatoxin
(C5a)-induced model of acute peritonitis [135].
RSV treatment attenuated mechanical ventilation-induced up-
regulation of pulmonary NFκB activity but without alteration of other
cytokines including IL-1β, IL-6, and keratinocyte-derived chemokine
(KC) in the lung, and TNF-α, KC and, IL-6 in plasma [136].
Finally, RSV treatment reduced the incidence and severity of
collagen-induced arthritis in a mouse model [137].
The summary of anti-inﬂammatory capacity of RSV in animal
models is demonstrated in Table 7.
4. Cardiovascular diseases
According to the WHO (http://www.who.int/cardiovascular_
diseases/about_cvd/en/), cardiovascular disease (CVD) includes disor-
ders of the heart and blood vessels, including hypertension (high
blood pressure), coronary heart disease (heart attack), cerebrovascular
disease (stroke), peripheral vascular disease, heart failure, rheumatic
heart disease, congenital heart disease, and cardiomyopathies. Rodent
animal models have been frequently used to evaluate the therapeutic
potential of drug candidates for the treatment of cardiovascular disease.
However, various test agents selected from such animal studies have
been found to be ineffective in clinical trials [138]. In terms of clinical
relevance for the treatment of cardiovascular diseases, biological exper-
imentation with pigs may offer an advantage over rodent studies, since
there is a closer resemblance to the human in terms of anatomy, physi-
ology, and genetics [139]. The effects of RSV on various cardiovascular
diseases are summarized in Table 8.
4.1. Restenosis
During vascular repair after re-vascularization or aortic injury, reste-
nosis might occur with neointimal hyperplasia. In earlier studies, RSV
treatment was shown to attenuate restenosis [140–142] with reduced
neointimal hyperplasia [140–144] in artery injury models of rabbits
[140], rats [141,143,144] and mice [142]. In addition, RSV upregulated
the expression of eNOS [141–143], p-eNOS [143], NO [142], Sirt1
[143], and p-AMPK [143] while it downregulated that of iNOS [143],platelet endothelial cell adhesion molecule (PECAM) [143], MMP-9
[143], 8-iso-PGF2α [144], MCP-1 [144], and IL-6 [144]. More recently,
it has been found that RSV treatment prevented restenosiswith a reduc-
tion of neointimal hyperplasia in carotid artery-injured [142–144] and
femoral wire-injured [143] models with rodents. The suppressive activ-
ity of RSV on neointimal hyperplasia was abolished in ER-α−/− mice
[142], endothelial NOS (eNOS) knockout mice [143], and in NG-nitro-
L-arginine methyl ester (L-NAME)-co-treated mice [142] or rats [143],
suggesting that RSV exerts the effect through ER-α-dependent NO pro-
duction [142].
With clinical signs of the protective effect of RSV on restenosis, RSV
induced arterial NOS activity and NO production in carotid artery
injured mice with high-fat diet [142], and reduced inﬂammatory medi-
ators including iNOS [143], platelet/endothelial cell adhesion molecule
[143], MMP-9 [143], 8-iso-PGF2α [144], MCP-1 [144] and IL-6 [144],
and induced eNOS, p-eNOS, Sirt1, and p-AMPK in carotid artery-
injured rats [143].4.2. Hypertension
Several experimental models with animals have been employed to
elucidate the effect of resveratrol on hypertension. Studies using spon-
taneously hypertensive rats (SHRs) [145–152] showed that RSV treat-
ment lowered systolic blood pressure (SBP) [145], prevented the
development of concentric hypertrophy [149], reduced myocardial ﬁ-
brosis [152], and improved endothelium-dependent vascular relaxation
in response to acetylcholine (Ach) [145,147] and myocardial perfor-
mance [148].
Also, RSV reduced oxidative DNA damage [146], glycoxidative stress
[146], and oxidative stress [148,149,152]. The molecular alterations by
RSV in SHRswere observed in the heartwith decreases in HNE-LKB1 ad-
duct and p-p70S6K expression, and increases in p-LKB1 and p-AMPK
[148]. In arteries of SHRs, ERK signal [150], PCNA expression [150],
and p-p70 S6 kinase [151] were decreased, but protein kinase G (PKG)
activity [150] and the expression levels of p-eNOS [151], LKB1 [151],
and AMPK [151] were increased by RSV intervention.
More recently, it has been shown that RSV supplementation attenu-
atedmonocrotaline-induced pulmonary hypertension in rats, with a de-
crease in right ventricular systolic pressure, right ventricular
hypertrophy, and medial thickening of intrapulmonary arteries. Also,
RSV increased pulmonary artery atrogin-1 expression [153].
RSV treatment improved survival without body weight loss,
protected against cardiac and aortic endothelial dysfunction, and nor-
malized reduced mitochondrial respiration, biogenesis, and mitochon-
drial fatty acid utilization. Related genes, including PPARα, carnitine
palmitoyltransferase Ib (CPT-1b), and middle-chain acyl-CoA dehydro-
genase, were normalized with RSV treatment in Dahl salt-sensitive
rats fed a high-salt diet [154].
RSV decreased mean arterial pressure and heart rate, diastolic and
systolic blood pressure, superoxide levels in the rostral ventrolateral
medulla, and serum estradiol, with adult-cycling female rats in which
hypertension was induced by chronic exposure of estradiol-17β [155].
RSV did not affect blood pressure, placental and renal blood ﬂows in
desoxycorticosterone acetate-induced hypertension in pregnant rats
(preeclampsia model) [156].
RSV improved ﬂow-mediated vasodilation, prevented increases in
systolic blood pressure, reduced hypertrophic growth of the myocardi-
um, decreased serum 4-HNE which is known to inhibit liver kinase B1
(LKB1) activity, together with increased phosphorylation of eNOS,
LKB1, and AMPK, and reduced phosphorylation of p70 S6 kinase (pro-
hypertrophic signaling) in mesenteric artery and ventricles in SHRs
and angiotensin-II hypertensive mice (LKB1–AMPK–eNOS signaling
axis) [151].
RSV treatment reduced the systolic blood pressure in rats with
fructose-induced hypertension, concomitant with a decrease in
Table 7
Anti-inﬂammatory effects of RSV in animal models (2009–2014).
Species Dose Duration Model Route Outcome Year Reference
Male BALB/c
mice
10 mg/kg 6 h (RSV treatment 15 min
before modeling)
C5a-induced model
of acute peritonitis
i.p. *Vascular permeability↓ (Increased peritoneal lavage↑)
*Neutrophil migration in peritoneum↓
*Serum: IL-1β↓, TNFα↓, IL-6↓, MIP-1α↓
2009 [135]
C57BL/10ScSn
(wild type) mice
20, 100, or
200 mg/kg/day,
daily
10 days (RSV treatment
2 days before modeling)
Hyper-acute Th1-type ileitis following
peroral infection with Toxoplasma gondii
Gavage *Extended survival
*Numbers of regulatory T cells and augmented
intestinal epithelial cell proliferation/regeneration in the ileum
mucosa↑
*Mucosal T lymphocyte and neutrophilic granulocyte numbers↓
*IL-10 in ileum, mesenteric lymph nodes and spleen↑
*Pro-inﬂammatory enterobacteria and
enterococci loads↓
*Anti-inﬂammatory lactobacilli and biﬁdobacteria loads↑
*Intestinal barrier functions↑
*IL-23p19↓, IFN-γ↓, TNF-α↓, IL-6↓, MCP-1↓
2010 [133]
Female C57BL/6
mice
3 mg/kg/day 3 weeks (co-exposure: DSS
for 5 days, RSV for 3 weeks)
Induction of chronic colitis by dextran
sulfate sodium (DSS)
In diet *Extended survival
*Loss of body weight, diarrhea and rectal bleeding↓
*TNF-α↓, IL-1β↓, PGES-1↓, COX-2↓, iNOS↓, IL-10↑
2010 [134]
Sprague–Dawley rats 20 mg/kg, once 3, 6, 12 h (RSV treatment 5 min
after modeling)
Taurocholate-induced severe acute
pancreatitis (SAP) by injecting 4%
sodium taurocholate at the hepatic
portal site
i.v.
(dorsal penile vein)
*Intestine: SOD↑, MDA↓, ICAM-1↑, VCAM-1↑
*Serum: TNFα↓
2012 [130]
Female Lewis rats 100 mg/kg/day 28 days, daily (RSV gavage
1 day after modeling)
Enterocolitis model by intramural
injections of peptidoglycan-
polysaccharide (PG-PS)
Gavage *Histologic ﬁbrosis score in cecal tissue↓
*No signiﬁcant effect on IGF-I, and procollagen type III
*Decreased IL-1β, IL-6, TNF-α, and TGF-β1
2012 [131]
Rabbit 50, 20, and
10 μmol/kg, daily
2 weeks (surgery 4 days
before RSV)
Experimental osteoarthritis using
the Hulth–Telhag modeling method
Knees injection *Cartilage destruction, the loss of matrix proteoglycan content in
cartilage↓
*Apoptosis rate of chondrocyte↓
*NO in the synovial ﬂuid↓
2012 [132]
Sprague–Dawley rats 20 mg/kg, once 3, 6, 12 h (SAP + RSV) Taurocholate-induced SAP induced by 4%
sodium taurocholate in the retrograde
pancreaticobiliary duct
i.v. *Histopathologic changes (saponiﬁcation spots in the intraperitoneal
cavity, severe pancreatic edema, hemorrhage, necrosis, etc.)↓
*Reduced renin activity and levels of angiotensin II, endothelin, and NO
in blood plasma
2013 [129]
Male DBA1 mice 20 mg/kg/day 8 weeks, daily (RSV
co-treatment with modeling)
Collagen-induced arthritis Gavage *Incidence and severity of rheumatoid arthritis↓ (reduction of inﬁltrated
cells in the joint, synovial hyperplasia, and adjacent cartilage, as bone
erosion)
2013 [137]
Mice 10, 20, and
40 mg/kg/day
5 h (RSV 1 h before MV for 4 h) Mechanical ventilation-induced
inﬂammation
i.p. *Pulmonary NFκB activity↓
*Lung: No effect on IL-1β, IL-6, keratinocyte-derived chemokine (KC)
*Plasma: No effect on TNF-α, KC, and IL-6
2014 [136]
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Table 8
Effects of RSV on cardiovascular diseases in animal models (2009–2014).
Species Dose Duration Model Route Outcome Marker Year Reference
Restenosis
Female ER-α−/−mice
(B6.129 Esr1tm1KskN10)
and their B6.129
wild-type littermates
50
mg/kg/day
4 weeks Mouse carotid artery injury
model with a high-fat diet
In diet *Restenosis (attenuated neointimal hyperplasia)↓
*Arterial eNOS activity↑*ER-α-dependent NO production↑
eNOS↑, NO↑ 2010 [142]
Sprague–Dawley rats 4 mg/kg/day 17, and 31
days
Carotid artery injury model s.c. *Neointimal hyperplasia↓
*Reduced iNOS, PECAM, and MMP-9 in the carotid artery at 4 days.
*Increased eNOS, p-eNOS in the carotid artery at 4 days.
*Increased SirT1 and p-AMPK higher than both untreated and
injured control carotid arteries at 4 days.
iNOS↓, eNOS↑, p-eNOS↑, SirT1↑↑,
p-AMPK↑↑, PECAM↓, MMP-9↓
2012 [143]
eNOS knockout mice 23
mg/kg/day
33 days Femoral wire injury model Oral *Neointimal hyperplasia↓
(No effect on neointimal formation in eNOS-KO mice)
Not available 2012 [143]
Rats 1 mg/kg/day 7 or 14
days
Balloon injury model of rat
carotid artery
i.p. *Neointimal hyperplasia↓
*Decreased neointimal/medial area↓
*Serum 8-iso-PGF2α levels in serum↓
*MCP-1 and IL-6 in injured arteries↓
8-iso-PGF2α↓, MCP-1↓, IL-6↓ 2013 [144]
Hypertension
Dahl salt-sensitive rat 18
mg/kg/day
8 weeks High-salt diet-induced
hypertension model
In diet *Survival↑
*Prevention from cardiac and aortic endothelial dysfunction
*Normalization of the reduced mitochondrial respiration,
biogenesis, and mitochondrial fatty acid utilization.
*Increases in peroxisome proliferator-activated receptor α
(PPARα), CPT-1β, and middle-chain acylCoA dehydrogenase
(MCAD) expression.
PPARα↑, CPT-1b↑, MCAD↑ 2011 [154]
Sprague–Dawley rats 0.84 g/kg of
chow
41 days Estradiol-17β-induced
hypertension model
In diet *Blood pressure↓
*Superoxide levels in rostral
ventral lateral medulla↓
*Serum estradiol↓
Estradiol↓ 2011 [155]
Sprague–Dawley rats 3 mg/kg/day 15 days Monocrotaline-induced
pulmonary hypertension model
Drinking
water
*Right ventricular systolic pressure↓
*Right ventricular hypertrophy↓
*Medial thickening of intrapulmonary arteries↓
*Normalization of pulmonary artery atrogin-1 expression
Atrogin-1↑ 2012 [153]
Wistar albino rats 20
mg/kg/day,
twice per
day
During
the whole
pregnancy
Desoxycorticosterone acetate
(DOCA)-induced hypertension
model
Orogastric *No effect on blood pressure
*No effect on blood ﬂows and placental pathology parameters
2012 [156]
Spontaneously
hypertensive rats
~146
mg/kg/day
5 weeks Spontaneously hypertensive rat
model
In diet *Vascular function↑
*Blood pressure↓
*Arterial eNOS and AMPK activities↑
*Cardiac HNE↓
*Left ventricular hypertrophy↓
*Cardiac LKB1/AMPK phosphorylation↑
Artery:
p-eNOS↑, p-LKB1↑, p-AMPK↑, p-p70 S6
kinase↓
2013 [151]
C57BL/6 mice ~320
mg/kg/day
2 weeks Angiotensin-II-induced
hypertension model
In diet *Vascular function↑
*Blood pressure↓
*Arterial eNOS and AMPK activities↑
*Cardiac HNE↓
*Left ventricular hypertrophy↓
*Cardiac LKB1/AMPK phosphorylation↑
Artery:
p-eNOS↑, p-LKB1↑,p-AMPK↑, p-p70 S6
kinase↓
2013 [151]
Rats 10
mg/kg/day
1 week or
4 weeks
Fructose-induced hypertension
model
In diet *Systolic blood pressure↓
*NADPH oxidase subunits and ROS↓
*NO and SOD2 levels↑
*p-AMPK, Akt and neuronal NOS in the nucleus tractus solitarii↑
NADPH oxidase subunits↓, NO↑, SOD2↑,
p-AMPK↑, Akt↑, nNOS↑
2014 [157]
Myocardial ischemia/infarction
Yorkshire miniswine 100 11 weeks Induced by implantation of an In diet *Regional wall motion abnormalities in the ischemic area↓ VEGF↑, p-eNOS↑, NFκB↑, p-Akt↑ 2010 [164]
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mg/kg/day ameroid constrictor on the left
circumﬂex artery in pigs fed a
high fat diet
*Myocardial blood ﬂow↑
*Endothelium-dependent coronary vessel function↑ (a response to
substance P↑)
*Mean arterial blood pressure, diastolic blood pressure↓
*Total cholesterol↓
*Increases in expression of VEGF, p-eNOS (ser1177), NFκB, and
p-Akt
Yorkshire miniswine 100
mg/kg/day
11 weeks Induced by implantation of an
ameroid constrictor on the left
circumﬂex artery in pigs fed a
high fat diet
Diet *Body mass index (BMI)↓
*Improved glucose tolerance, endothelial function, and myocardial
function
*Decreased free fatty acids, cholesterol, and c-reactive protein(CPR)
levels and insulin resistance in serum
*Induced insulin receptor substrate-1 (IRS), glucose transporters 1
(GLUT-1), and p-AMPK
*Reduced retinol binding protein 4 (RBP4).
CRP↓, IRS-1↑, GLUT-1↑, p-AMPK↑, RBP4↓ 2011 [165]
Rats 1 mg/kg/day,
daily
4 weeks Induced by permanent ligation of
the left anterior descending
artery
i.p. *Increased expression of adenylate kinase 1 (AK1) and
mitochondrial NADP+-dependent isocitrate dehydrogenase
(IDPm)
AK1↑, IDPm↑ 2011 [159]
C57BL/6 mice 20
mg/kg/day,
daily
42 days Induced by the left coronary
artery ligation
i.p. *Survival↑
*Delayed progression of cardiac remodeling
*Heart weight/body weight ratio↓
*Lung weight/body weight ratio↓
*Old infarct size↓
*Infarct size after global ischemia↓
2012 [158]
Rats 10 mg/kg,
single dose
150 min Induced by ischemia/reperfusion
injury
i.p. *Myocardial infarct area↓ 2013 [160]
Male Wistar rats 25
mg/kg/day
7 days Induced by ischemia/reperfusion
injury
i.p. *Recovery of post-ischemic ventricular functions↑
*Myocardial lipoperoxidation, free iron, and catalase activity
↓*Peroxidase activity, expression of Fe-SOD, and Mn-SOD↑
Fe-SOD↑, Mn-SOD↑, peroxidase activity↑,
catalase activity↓
2013 [161]
Yorkshire swine 100
mg/kg/day
11 weeks Induced by implantation of an
ameroid constrictor on the left
circumﬂex artery in pigs fed a
high fat diet
Diet *Body mass index↓
*No signiﬁcant difference in insulin signaling (AMPK, p-AMPK,
IRS2, p-IRS2, PI3K, Akt, p-Akt, FOXO1, p-FOXO1, GSK-3β, p-GSK-3β,
PGC1α, GLUT1, and GLUT4)
2013 [163]
Atherosclerosis
Rabbit 2 mg/kg/day 24 days Induced by
hypercholesterolemic diet
Diet *Aortic atherosclerotic lesions↓
*Intima area and the intima/media layer area ratio↓
*Decreased VCAM-1, MCP-1, and IL-6 concentrations in descending
aorta.
VCAM-1↓, MCP-1↓, IL-6↓ 2012 [166]
Mini pigs 0.114
mg/kg/day
12
months
Induced by
hypercholesterolemic diet
Diet *No alteration on LCL-c, HDL-c, TG in plasma
*No effect on ALT, GGT, ALT in serum
*Reduced collagens (COL1A, COL3A), lipoprotein lipase (LPL) and
fatty-acid binding proteins (FABPs) PBMNC
COL1A↓, COL3A↓, LPL↓, FABP↓ 2012 [168]
Mini pigs 0.257
mg/kg/day
4 months Induced by atherogenic diet Diet *Lipid drops in the intima of the aorta↓*Vascular oxidative stress↓
(superoxide anion↓)
*Suppressor of cytokine signaling 1 (SOCS1) in male PBMNC↓
*Female PBMNC: SOCS3↓, vinculin (VCL)↑
SOCS1↓, VCL↑ 2012 [169]
APOE*3-Leiden.CETP
(E3L.CETP) mice
11
mg/kg/day
14 weeks Induced by
hypercholesterolemic diet
Diet *Atherosclerotic lesion area in the aortic root↓
*Collagen/macrophage ratio in the atherosclerotic lesion↑
*Plasma cholesterol↓
*Macrophage function↑
Not available 2013 [167]
Others
Sprague–Dawley rats 0.7
mg/kg/single
dose
4 h 15
min
Angiotensin II (Ang-II)-induced
arteriolar leukocyte adhesion
model
i.v. *Arteriolar leukocyte adhesion in the mesenteric arterioles↓
*Leukocyte–endothelial cell interactions in the postcapillary
venules↓
Not available 2010 [175]
Sprague–Dawley rats 15
mg/kg/day,
daily
30 days Estrogen deﬁciency model by
ovariectomy
Oral
gavage
(p.o.)
*Leukocyte adhesion to the arteriolar endothelium↓ (venular
leukocyte–endothelial cell interactions↓)
*CINC/KC, MCP-1, and MIP-1α in circulating system↓
CINC/KC↓, MCP-1↓, MIP-1α↓, P-selectin↓,
VCAM-1↓
2010 [175]
(continued on next page)
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Table 8 (continued)
Species Dose Duration Model Route Outcome Marker Year Reference
*P-selectin and VCAM-1 in the arterial endothelium↓
Sprague–Dawley rats 2.5
mg/kg/day,
daily
24 days Cardiac hypertrophy by pressure
overload (abdominal aortic
banding surgery)
Oral
gavage
*Abnormalities in cardiac structure and function↓
*Oxidative stress in cardiac tissue↓
2010 [173]
C57BL/6J mice 100
mg/kg/day
6 weeks Abdominal aortic aneurysm
induced by periaortic application
of CaCl2
i.p. *Aneurysm size (decrease in aortic diameter)↓
*Inﬂammatory cell inﬁltration in the aortic wall↓
*Aortic wall:
Expression of MCP-1, TNF-α, p-p65, ICAM-1, CD68, VEGF-A, p47,
GPx1 and GPx3↓
8-OHdG-positive, Mac-2-positive, CD31-positive, and
4-HNE-positive cells↓
*Activities of MMP-2 and -9↓
MCP-1↓, TNF-α↓, p-p65↓, ICAM-1↓, CD68
↓, VEGF-A↓, p47↓, GPx-1↓, GPx-3↓,
8-OHdG↓, Mac-2↓, CD31↓, 4-HNE↓,
MMP-2↓, MMP-9↓
2011 [176]
Sprague–Dawley rats 10
mg/kg/day,
daily
21 days Abdominal aortic aneurysm
induced by elastase
Drinking
water
*Abdominal aortic aneurysm expansion↓
*Vessel wall macrophage inﬁltration↓
*CD62L-monocyte subset expansion↓ *CD143 monocyte expression
↓
*Plasma: MMP-9 activity↓, TNFα↓
*Abdominal aortic segments: MMP-9↓, VEGF↓, and TNFα↓
CD62L↓, CD143↓, MMP-9 activity↓,
TNFα↓, MMP-9↓, VEGF↓
2011 [177]
ICRWTmice (Nrf2+/+), ICR
Nrf2 KO mice (Nrf2−/−)
2.4 g/kg diet 16 weeks High fat diet-induced endothelial
dysfunction
Diet *Acetylcholine-induced vasodilations in skeletal muscle arterioles↑
*Oxidative stress and apoptosis in branches of the femoral artery↓
*Diminished RSV effects in Nrf2−/−mice.
2011 [177]
Sprague–Dawley rats 30
mg/kg/single
dose
2 h 30
min
Trauma-hemorrhage and
resuscitation model
i.v. *Normalized cardiac output and left ventricular performance
*Decreased DNA fragmentation (apoptosis), MPO activity, IL-6
levels, and ICAM-1 levels in cardiac tissue
*Increased p-Akt in cardiac tissue
MPO activity↓, IL-6↓, ICAM-1↓, p-Akt↑ 2012 [174]
C57BL/6 mice 10
mg/kg/single
dose
18 h Endotoxin-induced myocardial
toxicity
i.p. *Endotoxin-induced myocardial
injury↓
*Decrease in serum creatine kinase (CK) and lactate dehydrogenase
(LDH)
*End diastolic left ventricular inner dimension (LVID)↓
*Ejection fraction↑
*Decreased TNFα, IL-1β, MIP1α, MCP in the heart
*Possibly induced Nrf2 activation with HO-1 and
glutamate-cysteine ligase (GCLM) expression in heart tissue
CK↓, LDH↓, TNFα↓, IL-1β↓, MIP1α↓, MCP
↓, HO-1↑, GCLM↑
2013 [170]
Female C57BL6 mice ~320
mg/kg/day,
daily
8 weeks Cardiac injury/toxicity induced
by doxorubicin injection
Diet *Left ventricle remodeling↓
*Recovered exercise capacity
*Downregulated expression of molecular markers of cardiac
dysfunction [(atrial natriuretic peptide (ANP) protein], and 4-HNE
*Increased expression of mitochondrial function-related markers
(mitochondrial electron transport chain complexes, and
mitofusin-1 and -2)
ANP↓, 4-HNE↓, mitochondrial electron
transport chain complexes↑, mitofusin-1
↑ and -2↑
2013 [171]
Castrated male pigs 5 mg/kg/day,
daily
14 days Exposure to secondhand smoke Oral *Normalized cardiac function
*Left ventricular end-diastolic volume, cardiac output↑*Plasma
nitrotyrosine levels↓
*Decreased the increase in sarcomeric proteins (myosin light
chain-1 (MLC1), β-myosin heavy chain fragment, and myosin-7
fragments) metabolic enzymes (pyruvate dehydrogenase and
lactate dehydrogenase)
Nitrotyrosine, MLC1, β-myosin heavy
chain fragment, myosin-7 fragment,
pyruvate dehydrogenase, lactate
dehydrogenase
2013 [182]
Wistar albino rats 20
mg/kg/day,
daily
4 weeks Cardiac injury/toxicity induced
by doxorubicin injection
Oral
gavage
*Body and heart weights↑
*Left ventricular necrosis and ﬁbrosis↓
*Left ventricle: lipid peroxidation↓, hydroxyproline↓, TNFα↓, and
caspase-3↓, GSH↑, SOD↑
*Serum creatine kinase-myocardial band (CK-MB) activity↓
Hydroxyproline↓, TNFα↓, caspase-3↓,
CK-MB↓, GSH↑, SOD↑
2014 [172]
1086
E.-J.Park,J.M
.Pezzuto
/Biochim
ica
etBiophysica
A
cta
1852
(2015)
1071
–1113
1087E.-J. Park, J.M. Pezzuto / Biochimica et Biophysica Acta 1852 (2015) 1071–1113NADPH oxidase subunits (p67, p22-phox) and ROS, and an increase in
NO and SOD2, p-AMPK, Akt, and neuronal NOS [157].
4.3. Myocardial ischemia/infarction
RSV post-treatment increased survival and delayed the progression
of cardiac remodeling with a reduced heart weight/body weight ratio,
lung weight/body weight ratio, and old infarct size in a murinemyocar-
dial infarction model with global ischemia. In addition, RSV pretreat-
ment decreased infarct size when ex vivo murine hearts were exposed
to soluble fractalkine/chemokine (C-X3-C motif) ligand 1 (CX3CL1),
which was reported to exacerbate heart failure [158].
RSV pretreatment reversed the decrease in expression of adenylate
kinase 1 and mitochondrial NADP+-dependent isocitrate dehydroge-
nase (known to increase myocardial energetic efﬁciency and reduce
ROS-mediated damage) in surviving rats after permanent ligation of
the left anterior descending artery under isoﬂurane anesthesia [159].
RSV decreased the myocardial infarct area in ischemia-reperfusion
induced myocardial infarction in rats [160] and pretreatment improved
the recovery of post-ischemic ventricular functions, with decreases in
myocardial lipoperoxidation, free iron, and CAT activity, and increases
in peroxidase activity, expression of Fe-SOD and Mn-SOD in ischemia/
reperfusion (I/R)-induced injury with rats [161].
RSV supplements prevented an increase in body mass index and
blood glucose levels after dextrose infusion, and reversed the decrease
in cardioprotective autophagy in chronically induced ischemic myocar-
dium in pigs fed a high cholesterol diet, with normalization of increased
p-mammalian target of rapamycin (mTOR), decreased p70-S6K,
lysosome-associated membrane protein 2 (LAMP-2), and LC3A-II, to
levels of pigs fed a regular diet [162].
Although RSV supplement decreased body mass index, it did not
signiﬁcantly alter insulin signaling [AMPK, p-AMPK, insulin receptor
substrate-2 (IRS2), p-IRS2, PI3K, Akt, p-Akt, FOXO1, p-FOXO1, glycogen
synthase kinase 3β (GSK3β), p-GSK3β, PPARγ co-activator-1alpha
(PGC-1α), glucose transporter 1 (GLUT1), and GLUT4] in chronically in-
duced ischemic myocardiumwith pigs fed a high cholesterol diet [163].
RSV supplements attenuated regional wall motion abnormalities in
the ischemic area, increased myocardial blood ﬂow, preserved
endothelium-dependent coronary vessel functionwith an improved re-
sponse to substance P, and decreasedmean arterial blood pressure, dia-
stolic blood pressure, and total cholesterol, in chronically induced
ischemicmyocardiumwith pigs fed a high cholesterol diet, concomitant
with greater expression of VEGF (a potent vasodilator), p-eNOS
(ser1177) (which is involved in the generation of NO, a vasorelaxant),
NFκB (a transcription factor for VEGF), and p-Akt (Thr308) (pro-surviv-
al protein), in studies conducted with pigs fed a regular diet or a high
cholesterol diet [164].
With chronical ischemic myocardium in pigs fed a high cholesterol
diet, supplemental RSV 1) lowered body mass index, and 2) improved
each of the following: glucose tolerance with a decrease in blood glucose
levels 30 min after dextrose infusion, endothelial function with an
increase in microvascular relaxation response to ADP, and myocardial
functionswithdecreases in systolic bloodpressure, double product (pres-
sure-rate product, indirect index of myocardial oxygen consumption),
ventricular contractility assessment, and ventrical segmental shortening
[165]. RSV treatment also decreased free fatty acids, cholesterol, insulin
resistance, and C-reactive protein levels in serum.Notably, RSV treatment
led to induction of the downstream molecules of Sirt1 including IRS1,
GLUT1, and p-AMPK, and reduction of retinol binding protein 4 (RBP4),
which inhibits glucose uptake and blocks insulin signaling, in chronically
ischemic myocardium in pigs fed a high cholesterol diet [165].
4.4. Atherosclerosis
Both short-term (24 days [166] and 14 weeks [167]) with a higher
dose (2 [166] and 11 [167] mg/kg/day) in rabbits [166] and mice[167], and long-term (12 [168] and 4 [169] months) with a lower dose
(0.114 [168] and 0.257 [169] mg/kg/day) of RSV in mini pigs displayed
a protective effect on atherosclerosis.
RSV treatment resulted in milder aortic atherosclerotic lesions, a
reduced intima area and intima/media layer area ratio, and decreased
vascular cell adhesionmolecule 1 (VCAM-1), MCP-1, and IL-6 in the de-
scending aorta of rabbits with hypercholesterolemic diet-induced ath-
erosclerosis [166].
RSV treatment reduced the atherosclerotic lesion area of the aortic
root, increased the collagen/macrophage ratio in atherosclerotic lesions
(a marker of plaque stability) decreased plasma cholesterol levels, and
improved macrophage function in APOE*3-Leiden.CETP (E3L.CETP)
mice fed a cholesterol-rich diet [167].
RSV treatment reduced collagens (COL1A, COL3A), lipoprotein lipase
and fatty-acid binding proteins in peripheral blood mononuclear cells
(PBMNC) of high-fat diet pigs [168]. RSV treatmentmoderately alleviat-
ed atherosclerosis by reducing lipid drops in the intima of the aorta, de-
creasing vascular oxidative stress (decreased superoxide anion),
decreasing suppressor of cytokine signaling 1 (SOCS1) inmale PBMNCs,
and decreasing SOCS3, and increasing vinculin in female PBMNCs in pigs
fed an atherogenic diet [169].
4.5. Other cardioprotective effects
RSV pretreatment attenuated LPS-inducedmyocardial injury inmice
(sepsis-related myocardial injury; septic cardiomyopathy), with
decreased end diastolic left ventricular inner dimension, serum creatine
kinase (CK) and LDH, as well as increased the ejection fraction. In addi-
tion, RSV inhibited the expression of proinﬂammatory mediators in-
cluding TNF-α, IL-1β, MIP-1α, and MCP in heart tissue, while it
induced the expression of HO-1 and glutamate-cysteine ligase regulated
by Nrf2 activation [170].
RSV pretreatment attenuated left ventricular remodeling and led to
a recovery in exercise capacity, with a decrease in the expression of
molecular markers of cardiac dysfunction (atrial natriuretic peptide),
and oxidative stress (4-HNE), and an increase in the expression of mito-
chondrial function-related markers (mitochondrial electron transport
chain complexes, and mitofusin-1 and -2) in a doxorubicin-induced
mouse cardiac injury model [171].
In a doxorubicin-induced rat cardiac injurymodel, RSVpretreatment
attenuated a decrease in body and heart weights as well as an increase
in left ventricular necrosis and ﬁbrosis, reduced left ventricular lipid
peroxidation, hydroxyproline, TNF-α, caspase-3 levels, and serum crea-
tine kinase-myocardial band (CK-MB) activity, and restored left ventric-
ular reduced glutathione content and SOD activity [172].
RSV post-treatment attenuated cardiac hypertrophywith a decrease
in abnormalities in cardiac structure and function in pressure overload
rats induced by abdominal aortic banding surgery [173].
RSV pretreatment normalized cardiac output and left ventricular
performance (±dP/dtmax), with a decrease in DNA fragmentation
(apoptosis),myeloperoxidase (MPO) activity, IL-6 levels, and intercellu-
lar adhesion molecule 1 (ICAM-1) levels, and an increase in p-Akt with
cardiac tissues, with a trauma-hemorrhage and resuscitation model
performed with rats [174].
4.6. Other vascular protective effects
RSV pretreatment inhibited angiotensin II-induced arteriolar leuko-
cyte adhesion in mesenteric arterioles, and leukocyte–endothelial cell
interactions, in the postcapillary venules of rats [175], and attenuated
ovariectomy (animal model of estrogen deﬁciency)-induced 1) leuko-
cyte adhesion to the arteriolar endothelium, 2) venular leukocyte–
endothelial cell interactions, 3) increase of circulating levels of CINC/
KC, MCP-1, and MIP-1α, and 4) upregulation of P-selectin and VCAM-
1 in the arterial endothelium of rats [175]. Pretreatment also showed
protective effects on abdominal aortic aneurysm in both CaCl2-
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eurysm expansion, inﬂammatory cell inﬁltration, and molecular
markers related to inﬂammation, oxidative stress, matrix proteolysis,
etc. [176,177].
RSV pretreatment attenuated the expansion of abdominal aortic an-
eurysm as judged by reduced aneurysm size (decrease in aortic diame-
ter) and inﬂammatory cell inﬁltration in the aortic wall of mice. At the
molecular level in the aortic wall, RSV decreased i) mRNA expression
of MCP-1, TNF-α, ICAM-1, CD68, VEGF-A, p47, glutathione peroxidase 1
(GPx-1), and GPx-3, ii) 8-hydroxy-2′-deoxyguanosine (8-OHdG)-
positive, Mac-2-positive, CD31-positive, and 4-HNE-positive cells, iii)
the activities of MMP-2 and MMP-9, and iv) phosphorylation of p65
[176]. With abdominal aortic segments from the rat with abdominal
aortic aneurysm [177], RSV pretreatment decreased CD62L-monocyte
subset expansion, CD143 monocyte expression, MMP-9 activity and
TNF-α levels in plasma, and expression of MMP-9, VEGF, and TNF-α.
RSV supplementation displayed protective effects on high fat diet-
induced endothelial dysfunction in Nrf2 wild type mice (Nrf2+/+),
with increased acetylcholine-induced vasodilations in skeletal muscle
arterioles, decreased oxidative stress and apoptosis in branches of the
femoral artery. The protective effects of RSV were partially abolished
in Nrf2−/−mice receiving a high fat diet, suggesting that the RSV effects
are mediated by Nrf2 [178].
RSV treatment increased renal blood ﬂow (RBF) and decreased renal
vascular resistance in rats. However, upon L-NAME (a NOS inhibitor)
and tempol (a SOD mimetic) pretreatment, but not indomethacin
(a COX inhibitor) pretreatment, the increase in RBF by RSV was dimin-
ished, indicating that the renal vasodilatory effect of RSV is related toNO
production and superoxide scavenging [179].
RSV signiﬁcantly accelerated re-endothelialization (decreasing the
risk of thrombosis) in mice fed a high-fat diet with carotid artery injury
[180].
Finally, RSV treatment increased muscle microvascular blood vol-
ume at 30, 60, and 90 min, and muscle microvascular blood ﬂow at 30
and 60min. However, systemic pretreatment with L-NAME (NOS inhib-
itor) and TNF-α (known to induce ROS generation) neutralized the
vasodilatory effect of RSV on muscle microvasculature, suggesting that
the effect is exerted by increasing vasorelaxant NO as well as reducing
TNF-α-induced ROS production [181].
The effects of RSV on various cardiovascular diseases are summa-
rized in Table 8.5. Diabetes
With diabetic animal models, more than half of the reported studies
involved induction of diabetes by treatment with streptozotocin (STZ).
STZ is used for the production of insulin-dependent (type I) diabetes
mellitus via damage of pancreatic beta-cells that occurs within 48 h
and lasts for up to 4months [183]. In linewith this, the duration of stud-
ies with RSV varied from 6 days to 4 months which fall into the
abovementioned range. RSV administration ameliorated diabetic symp-
toms, including body weight loss, polyphagia, polydipsia, delayed onset
of insulin resistance, and increased glucose uptake by hepatocytes, adi-
pocytes, and skeletal muscle, and hepatic glycogen synthesis in diabetic
rodents. Diabetes eventually can lead to the onset of complications in-
cluding cardiomyopathy, nephropathy, neuropathy (e.g., autonomic
neuropathy predisposing to gastroparesis and peripheral sensory neu-
ropathy predisposing to foot ulcers), ketoacidosis, vasculopathy
(e.g., retinal vasculopathy), hypertension, stroke, and hyperosmolar
hyperglycemic nonketotic syndrome [184]. Treatment with resveratrol
resulted in the alleviation/amelioration of diabetic complications with
normalized/recovered clinical/biochemical markers in diabetic animal
models, suggesting potential anti-diabetic activity. In the component
of this review dealing with animals, only effects of RSV with the STZ-
induced model are described.Although some studies have reported that RSV had no effect on
blood glucose levels [185,186], the majority of publications show re-
duced blood glucose levels (hypoglycemic effect) [187–192]. In fact,
RSV delayed the onset of insulin resistance with increased glucose
uptake by hepatocytes, adipocytes, and skeletal muscle, and increased
hepatic glycogen synthesis in diabetic rodents [187]. In addition, RSV
treatment resulted in a hypolipidemic effect with decreased plasma
trigylcerides [187].
Elevated levels of oxidative/nitrosative stress markers including
i)MDA, xanthine oxidase (XO), andNO in the hippocampus, cortex, cer-
ebellum, brain stem, and spinal cord [193], ii) MDA in plasma/blood
[190,194,195], iii) peroxynitrite in plasma [194], and iv) TBARS in the
kidney [186], were decreased by RSV treatment. The levels of Trx-1
[189] in the heart, and the activities of antioxidant enzyme including
i) CAT in plasma/blood [194,195] and sciatic nerve [194], and
ii) MnSOD in the heart [189] and SOD in the kidney [186], were
increased by RSV treatment. Additional alterations observed with STZ-
induced diabetic ratswere also reversed by RSV intervention. RSV atten-
uated body weight loss [187], and reduced the symptoms of nephropa-
thy by inhibiting the increase in kidneyweight/bodyweight ratio [186],
plasma creatinine level [186,191], blood urea nitrogen (BUN) [186], and
blood urea [191].
RSV attenuated neuropathy, for instance, RSV reversed the STZ-
induced enhancement of contractile responses to noradrenaline (NA)
[190] and the decrease in the relaxation response to acetylcholine
(Ach) [190]. Also, RSV suppressed polyphagia [187], polydipsia [187],
cold allodynia [196], and hyperalgesia [194,196,197], while it normal-
ized decreased motor nerve conduction velocity (MNCV) and nerve
blood ﬂow (NBF) [194].
RSV treatment decreased the enzyme activities of aspartate trans-
aminase (AST), alanine transaminase (ALT), and ALP [191] in serum,
and suppressed the expression levels of p38 and p53 in the kidney
[186], Cav-1 [192] in the heart, and p-Akt (S473) in the soleus muscle
[188]. On the other hand, RSV increased p-AMPK [192], p-Akt [189,
192], p-eNOS [189,192], HO-1 [189], GLUT-4 [192], Cav-3 [192], and
VEGF [189] in the heart, and SIR2, p-histone H3 in the kidney [186]. In
addition, treatment improved left ventricular function throughout re-
perfusion with decreased infarct size and cardiomyocyte apoptosis in
the global ischemia model [189].
Collectively, RSV ameliorated various diabetic symptoms and
complications in STZ-induced diabetic animal models, with underlying
molecular mechanisms including a reduction in oxidative/nitrosative
stress and inﬂammation generated during high-glucose metabolism,
and the induction in signaling pathways such as AMPK and Sirt.
Biomarkers altered by RSV in STZ-induced diabetic models are listed
in Table 9.
5.1. Effects of RSV on circulating/systemic biomarkers
Recent studies report that the unfavorable alterations observed in the
circulatory and vascular systems of STZ-induced diabetic rodents were
improved by treatment with RSV. This includes amelioration of
deregulated biomarkers related to hyperglycemia, hyperlipidemia, oxida-
tive stress, inﬂammation, liver dysfunction, and renal dysfunction in the
blood/serum/plasma of diabetic rodents. RSV treatment reduced STZ-
induced hyperglycemiawith 1) a decrease in blood/plasma glucose levels
[187,189–192,203,207,211,222,226,228,229], plasma fructosamine
(a glycated protein) [217], serum advanced glycation end products
[200], and blood glycosylated hemoglobin (HbA1c) [211], and 2) an in-
crease in plasma insulin [191,211], adiponectin [200] and C-peptide
[200] levels.
Oxidative or nitrosative stress-related markers, which were altered
in STZ-induced diabetic rodents, were reversed by RSV treatment. RSV
treatment reduced plasma lipid peroxidation [211,222] with decreased
levels of plasma MDA [190,194,195,207]. Additional decreases in
reactive oxygen/nitrogen levels including blood NO [211], plasma
Table 9
Effects of RSV on biomarkers altered by STZ in animal models (2009–2014).
Marker Tissue (A: activity, P: phosphorylation, E: expression, I/R: upon ischemia/reperfusion injury, ↑↑ higher than basal level)
Proteins
Acetylcholinesterase (AChE) Cerebral cortex synaptosome↓ [198], hippocampus↓ [199]
Advanced glycation end products (AGE) Serum↓ [200]
Alkaline phosphatase (ALP), activity Serum↓ [191,201], blood↓ [202]
5′ AMP-activated protein kinase (AMPK) Lipid raft fraction in left ventricle↑P [192], kidney↑P/E [203], hippocampus↑P [204], liver↑A [205]
Alanine aminotransferase (ALT), activity Serum↓ [206], kidney↓ [200], serum↓ [191,201,207]
Aspartate aminotransferase (AST), activity Serum↓ [206], kidney↓ [200], serum↓ [191,201,207]
Aminolevulinate dehydratase (δ-ALA-D), activity Liver↑ [206], kidney↑ [206]
AKT, phosphorylated Left ventricle↑ [192], kidney↓ [208], I/R left ventricular tissue↑ [189] and I/R heart↑ [209]
Bilirubin Serum↓ [201,207]
Catalase, activity I/R brain↑ [210] liver↑ [201,206], kidney↑ [206], sciatic nerve sections↑E [194], blood↑ [202], red cell↑ [195], pancreas↑ [211]
Cav-1 Lipid raft fraction in left ventricle↓ [192]
Cav-3 Lipid raft fraction in left ventricle↑ [192]
Plasma ceruloplasmin Plasma↑ [211]
Citrate synthase, activity Heart↓A [212]
Collagen IV Glomeruli↓ [213], cortex↓ [214]
COX-1 Heart↔ [215], kidney↔ [216]
COX-2 Heart↔ [215], kidney↔ [216]
ERK1/2 Aortic tissue↓A [217], kidney↓P [213]
Fibronectin Glomeruli↓ [213], cortex↓ [214]
FoxO1 Kidney↑ [214]
FOXO3a Corpora cavernosa↓ [218]
Fructosamine Plasma↓ [217]
Fructose-1,6-bisphosphatase Kidney↓ [219], liver↓ [219]
Glucose-6-phosphatase Kidney↓ [219], liver↓ [219]
Glucose-6-phosphate dehydrogenase Kidney↑ [219], liver↑ [219]
γ-Glutamiltransferase (γ-GT), activity Serum↓ [206]
Glucose transporter type 4 (GLUT-4) Lipid raft fraction in left ventricle↑ [192], soleus muscle↑ [188]
Glutathione Cardiac tissue↑ [212], liver↑ [207], liver GSH↑ [201], blood↑ [202], plasma↑GSH [211]
Glutathione reductase, activity Cardiac tissue↑A [212]
Glutathione peroxidase (GPx) Liver↑ [201], blood↑ [202], pancreas↑ [211]
Glutathione-S-transferase Liver↑A [207], pancreas↑A [211]
Glycogen synthase Liver↑ [219]
Glycogen phosphorylase Liver↑ [219]
Hexokinase, activity Kidney↑ [219], liver↑ [219]
Histone H3 Kidney↓dephosphorylation [186]
HO-1 I/R left ventricle↑ [189]
β-Hydroxyacyl coenzyme-A dehydrogenase, activity Heart↓A [212]
Insulin Plasma↑ [191,211]
Intercellular adhesion molecule-1 (ICAM-1) Thoracic aorta and carotid artery↓ [220], renal cortex↓ [208]
IL-1β Serum↓ [220], plasma↓ [211], kidney↓ [200,203], liver↓ [201,221]
IL-6 I/R brain↓ [210], serum↓ [220], kidney↑ [203], kidney↓ [200], liver↓ [201], hippocampus↓ [204], plasma↓ [222],
plasma↓ [211]
IL-10 I/R brain↑ [210]
Lactate dehydrogenase (LDH) Kidney↓ [219], liver↓ [219]
MCP-1 Thoracic aorta and carotid artery↓ [220]
Myeloperoxidase (MPO) I/R brain↓ [210]
MMP-9 Heart↔ [215]
NFκB Heart↔E [215] Aortic tissue↓E [217], thoracic aorta and carotid artery↓A/E [220], kidney↓E [208], kidney↓E [200],
liver↓E [221], hippocampus↓E [204], gastrocnemius muscle↓A [205], polymorphonuclear cells↓A [222], pancreas↓A [211]
p-eNOS, endothelial, phosphorylated Heart↑ [192], I/R left ventricular tissue↑ [189]
eNOS, endothelial Heart↑ [209], microvessel↑↑(more than basal level) [223]
iNOS, inducible Heart↓ [209]
nNOS, neuronal Heart↓ [209], microvessel↑↑ [223]
NTPDase Brain (cerebral cortex synaptosomes)↑A [198]
5′-Nucleotidase Brain (cerebral cortex synaptosomes)↑A [198]
p38 Kidney↓ [186]
p53 Kidney↓ [186], corpora cavernosa↓ [218]
p62 Heart↓ [224]
PAI-1 expression Renal cortex↓ [208]
Phosphoenolpyruvate carboxykinase (PEPCK) Liver↑ [188]
Proliferation cell nuclear antigen (PCNA) Aortic tissue↓ [217], glomeruli kidney↓ [208]
Pyruvate dehydrogenase, activity Heart↑A [212]
Pyruvate kinase, activity Kidney↑ [219], liver↑ [219]
Quinone reductase Liver↑A [207]
Rab7 Heart↑ [224]
RAGE Aortic tissue↓ [217]
SERCA2a Heart↑ [225]
SirT1 Heart↑E [215,224], heart↑A [224,225], kidney↑E [214], liver↑A [205], corpora cavernosa↑E [218]
SIR2 Kidney↑E [186]
Smad2 Kidney↓P [213]
Smad3 Kidney↓P [213]
SOD, activity I/R brain↑ [210], liver↑ [201,206,207,226], aortic tissue↑ [226], kidney↑ [206] kidney↑ [214], blood↑ [202,222], pancreas↑
[211], corpora cavernosa↑ [218]
(continued on next page)
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Table 9 (continued)
Marker Tissue (A: activity, P: phosphorylation, E: expression, I/R: upon ischemia/reperfusion injury, ↑↑ higher than basal level)
MnSOD, activity I/R left ventricle↑A [189], liver↓E [221], spleen↑E [221]
TNF-α I/R brain↓ [210], thoracic aorta and carotid artery↓ [220], kidney↑ [203], kidney↓ [200], liver↓ [201], hippocampus↓ [204],
serum↓ [197], plasma↓ [211,222]
TGF-β Glomeruli↓ [213]
Trx-1 I/R left ventricle↑ [189]
VEGF I/R left ventricle↑ [189], hippocampus↓ [204]
Xanthine oxidase (XO) Hippocampus, cortex, cerebellum, brain stem and spinal cord↓ [193]
Antioxidant-related
Hydrogen peroxide Liver↓ [201], plasma and pancreatic tissues↓ [211]
Hydroxyl radical Kidney↓ [200]
Lipid peroxidation/lipid peroxide Liver↓ [201,206], kidney↓ [206,227], plasma↓ [211,222], pancreas↓ [211]
Malondialdehyde (MDA) I/R brain↓ [210], liver↓ [207,226], aortic tissue↓ [226], plasma↓ [190,194,195,207], kidney↓ [214], hippocampus, cortex,
cerebellum, brain stem and spinal cord↓ [193], corpora cavernosa↓ [218]
Nitric oxide (NO) Kidney↓ [200], liver↓ [201], brain↓ [197], hippocampus, cortex, cerebellum, brain stem and spinal cord↓ [193], blood↓ [211],
I/R plasma↑ [209]
Nitrotyrosine I/R heart↓ [209]
Non protein thiol Liver↑ [206], kidney↑ [206]
Peroxynitrite Plasma↓ [194]
Protein carbonyl Kidney↓ [203], liver↓ [201,221], spleen↓ [221], plasma and pancreas↓ [211]
Superoxide anion Kidney↓ [200,203], liver↓ [221], spleen↓ [221], I/R plasma↓ [209], brain↓ [223]
Vitamin C Liver↑ [201,206], kidney↑ [206], plasma↑ [211]
Vitamin E Liver↑ [201], plasma↑ [211]
Glucose-related
Blood/serum glucose ↓ [187,189–192,203,211,222,226,228,229]
Glycogen, liver ↑ [187,219]
Glycosylated hemoglobin (HbA1c) Blood↓ [211]
Kidney-related
Creatinine ↓Plasma [203], serum↓ [206,227,228]
Kidney weight to body weight ratio ↓ [213]
Urea nitrogen Blood↓ [203]
Urea Serum↓ [206], kidney↓ [227]
Lipid-related
Cholesterol, serum ↓ [206,207,229]
Fatty acid Serum↓ [212]
Hypolipidemic ↑ [226]
Triglyceride, serum/plasma ↓ [187,206,207]
Nerve-related
Cerebral infarction (cerebroprotective) ↓ [210]
Motor nerve conduction velocity (MNCV) ↑ [194]
Nerve blood ﬂow (NBF) ↑ [194]
Other factors
Autophagic dysfunction (autophagic ﬂux) ↓ [224]
Weight ↑ [190,222]
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oxide [211], and plasma protein carbonyl [211]were reported as a result
of treatment, along with increases in plasma levels of antioxidants in-
cluding reduced glutathione [211], vitamin C [211], vitamin E [211],
and ceruloplasmin [211], aswell as the activities of antioxidant enzymes
in blood including GPx [202], CAT [202], and SOD [202,222].
As mentioned above, hyperlipidemia, one of the diabetic complica-
tions, can be alleviated by RSV treatment [226], and this is associated
with a decrease in total cholesterol [206,207,220,229], triacylglycerol
[206,207,220], low-density lipoprotein (LDL) [207], and total cholester-
ol to high-density lipoprotein (HDL) ratio [207] in serum.
RSV treatment attenuated diabetic inﬂammation, accompanied by
downregulated expression levels of IL-1β [211,220], IL-6 [211,220,
222], NFκB [211], and TNF-α [197,211,222] in serum or plasma.
Liver function damage caused by STZ can be inhibited by RSV
treatment with modiﬁcation of related biomarkers. RSV treatment
reversed the elevated enzymatic activities of alanine aminotransfer-
ase (ALT) [191,201,206,207], aspartate aminotransferase (AST) [191,
201,206,207], γ-glutamiltransferase (γ-GT) [206], and ALP [191,
201], and abolished the increased levels of bilirubin [201,207] in
serum.In relation to nephropathy, RSV treatment ameliorated renal dys-
function as judged by lowering plasma creatinine [203] and blood
urea nitrogen [203].5.2. Effects of RSV on blood vessels
RSV treatment inhibited STZ-induced vasculopathy [217] in rodents.
RSV decreased i) vascular permeability in the aorta [217], retina [217],
kidney [217], and blood–brain barrier [204], ii) vascular smooth muscle
cell proliferation [217], and iii) aortic collagen deposition/cross-linking
[217], whereas it normalized the impaired vascular reactivity/response
(e.g., increased endothelium-dependent relaxation upon acetylcholine
exposure in the aortic ring) [190,226]. In addition, the expression levels
of biomarkers in blood vessels of diabetic rodents were altered by RSV
treatment. The expression levels of ICAM-1 [220], MCP-1, chemokine
(C-Cmotif) ligand 2 (CCL2) [220], TNF-α [220], and NFκB (total and nu-
clear) in the thoracic aorta and carotid artery [220] were downregulat-
ed. Also, the expression levels of PCNA [217], p-ERK1/2 [217], receptor
for advanced glycation end product [217], and nuclear NFκB [217] in
aortic tissue were decreased.
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Treatmentwith RSV can alleviate heart dysfunction (diabetic cardio-
myopathy), one diabetic complication, accompanied with reversion of
the expression or activity of biomarkers or biochemical parameters
which are altered in STZ-induced dibetic rodents. RSV treatment less-
ened i) cardiomyocyte apoptosis with downregulation of autophagic
ﬂux [224], ii) collagen deposition [225], and iii) atrial cardiac stem/
progenitor cell loss [230].
RSV treatment increased i) the expression of Sirt1 [215], Rab7
(a crucial factor in the maturation of autophagosomes and their fusion
with lysosomes) [224], GLUT4 [192], and caveolin-3 [192], eNOS [209],
sarcoplasmic calcium ATPase 2a (SERCA2a; improves contractile dys-
function) [225], and glutathione [212], ii) enzymatic activities of pyru-
vate dehydrogenase [212], GR [212], and iii) phosphorylations of
AMPK [192], eNOS [192], and Akt [192] were reverted to the normal
condition with resveratrol treatment. Also, RSV decreased the expres-
sion of caveolin-1 [192], p62 protein [224], neuronal NOS (nNOS)
[209], iNOS [209], the enzymatic activities of myocardial β-
hydroxyacyl coenzyme-A dehydrogenase [212], and citrate synthase
[212].
In addition, upon acute myocardial I/R injury, RSV treatment im-
proved cardiac function upon I/R exposure, and decreased infarct size
[189,209]. The downregulated expression of cardiac p-Akt (Ser473)
[189,209], p-eNOS [189], thiredoxin-1 (Trx-1) [189], HO-1 [189], plas-
ma NO, and the enzymatic activity of Mn-SOD [189], and upregulated
cardiac nitrotyrosine and plasma superoxide anion, were reversed by
RSV treatment in diabetic rats [209].
5.4. Effects of RSV on the kidney
RSV treatment ameliorated hyperglycemia-mediated renal dysfunc-
tion or diabetic nephropathy (e.g., oxidative damage [200],
microalbuminuria [213]/proteinuria [227,228], glomerular hypertrophy
[213], renal hypertrophy [228], glomerulosclerosis [213]), by lowering
i) urinary levels of urea [206], creatinine [206,228], albumin [213], and
albumin to creatinine ratio [208], ii) kidney weight to body weight
ratio [208], iii) thickness of the glomerular basement membrane
(GBM) [213], and iv) vascular leakage (capillary permeability) [217].
In renal tissue, RSV treatment attenuated increased levels of proin-
ﬂammatory proteins including IL-1β [200,203], IL-6 [200,203], TNF-α
[200,203], andNFκB [200,208]. However, RSV did not signiﬁcantly affect
the expression of renal COX-1 and -2 genes in diabetic rats [216].
RSV treatmentmight reduce renal tissue ﬁbrosis, with the inhibition
of TGF-β signaling by decreasing TGF-β [213] levels and the phosphor-
ylation of smad2 [213] and smad3 [213], and subsequent expression
of extracellularmatrixmolecules (ﬁbronectin [213] and type IV collagen
[213]) in diabetic glomeruli. Also, increased levels of ﬁbronectin and
type IV collagen in the renal cortex were decreased by RSV in STZ-
induced diabetic rats [214]. RSV decreased p-ERK1/2 [213] which is re-
lated to hypertrophy and extracellular matrix accumulation in the renal
tissue of rodents.
RSV treatment had effects on carbohydrate metabolism-related
enzymes in diabetic kidney, with inhibition of enzymatic activities
of LDH [219], glucose 6-phosphatase [219], and fructose 1,6-
bisphosphatase [219], and induction of the enzymatic activities of hexo-
kinase [219], pyruvate kinase [219], and glucose 6-phosphate dehydro-
genase [219].
RSV treatment alleviated oxidative stress in the STZ-induced diabet-
ic kidney in rodents, as judged by induction of the expression of Nrf2
[200], γ-glutamylcysteine synthetase heavy subunit [200], glutathione
S-transferase (GST), mu 3 [200], and enhancing the enzymatic activities
of CAT [200,206,214], SOD [200,206,214], GPx [200], GST [200], GR
[200], glyoxalase-I [200] and aminolevulinic acid dehydratase (δ-ALA-
D) [206]. RSV also increased the levels of nonprotein thiols (liver/
renal), and vitamins C [200,203] and E [200], and reduced glutathione[200], while it decreased the levels of superoxide anion [200,203],
TBARS levels [206], hydroxyl radical [200], NO [200], protein carbonyl
[203], and MDA [214] in diabetic kidney.
In relation to vascular complications in the diabetic renal cortex, RSV
treatment reversed the increased expression of plasminogen activator
inhibitor-1 (PAI-1) (ﬁbrosis and thrombosis) [208], intercellular adhe-
sion molecule-1 (inﬁltration of leukocytes) [208], and the p-Akt/Akt
ratio [208].
In relation to the glomerular ﬁltration, RSV reversed the decrease of
nephrin in the glomeruli of the diabetic kidney [213]. Also, in the diabet-
ic kidney, RSV treatment enhanced the AMPK–Sirt1 pathway with up-
regulated expression levels of the p-AMPK [203], AMPK [203], Sirt1
[186,214], and FOXO1 [214], and decreased expression levels of dephos-
phorylated histone H3 [186] and p53 [186].
5.5. Effects of RSV on the hepatic system
RSV treatment resulted in the attenuation of liver dysfunction in-
duced by STZ in rodentmodels. Treatment preserved the cellular function
and structural integrity of hepatocytes fromhyperglycemia-mediated ox-
idative damage [201], and demonstrated antihyperglycemic potential
with improved hepatic glycogen content [219].
Treatment with RSV signiﬁcantly decreased oxidative stress via
i) reducing the levels of TBARS [206], superoxide anion [221], hepatic
lipid peroxides [201], hydroperoxides [201], protein carbonyls [201],
MDA [221,226], protein carbonyl [221], and NO [201], and ii) increasing
the levels of reduced glutathione [207], vitamin C [201,206], vitamin E
[201], reduced glutathione [201], nonprotein thiols [206], hepatic glyco-
gen [219],Mn-SOD [221], aswell as increased the enzymatic activities of
GST [201,207], GR [201], NAD(P)H: quinone oxidoreductase (NQO)
[207], CAT [201,206,207], SOD [201,206,207,226], δ-ALA-D [206], and
GPx [201].
RSV treatment decreased inﬂammation markers including TNF-α
[201], IL-1β [201,221], IL-6 [201], and NFκB [201,221], and normalized
liver function-related enzymes, including downregulation of the enzy-
matic activities of hepatic aspartate transaminase (AST) [201], ALT
[201], and ALP [201].
RSV attenuated STZ-induced alteration in carbohydratemetabolism-
related enzymes by i) reducing the activity of LDH [219], glucose 6-
phosphatase [219], fructose 1,6-bisphosphatase [219], glycogen phos-
phorylase [219], and phosphoenolpyruvate carboxykinase [188], and
by ii) enhancing the activities of hexokinase [219], pyruvate kinase
[219], glucose 6-phosphate dehydrogenase [219], and glycogen
synthase [219] in the liver.
RSV treatment normalized energy metabolism with increased ex-
pression of hepatic AMPK and Sirt1, andmitochondrial biogenesis [205].
5.6. Effects of RSV on the central nervous system
Neurological complications or diabetic encephalopathy, including
cognitive impairment with decreased hippocampal neurogenesis and
synaptic plasticity, neuropathic pain, and cerebral infarction results
from chronic hyperglycemia and subsequent oxidative stress. RSV treat-
ment exhibited beneﬁcial effects on diabetic brain with a decrease in
neuropathic pain (thermal hyperalgesia [194,196,197], cold allodynia
[196]), sensory neuropathy (e.g., thermal hypoalgesia with an increase
in intraepidermal nerve ﬁber loss and the mean axonal diameter of
myelinated axons of the tibial nerve [231]), cerebral infarction upon
I/R exposure [210], neurodegeneration [204] (the reduction in motor
nerve conduction velocity [194], nerve blood ﬂow [194], DNA damage
and apoptosis in sciatic nerve sections [194]), memory impairment
[199], anxiety [232], and neuroinﬂammation (astrocytic activation)
[204].
RSV decreased the apoptosis rate in the retina and sciatic nerve of
diabetic rats [222], and exhibited a cerebroprotective effect against ce-
rebral infarction, as judged by reduced oxidative stress markers (MPO
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antioxidant (SOD and CAT) and anti-inﬂammatory markers (IL-10) in
I/R-damaged brain tissue [210]. Inﬂammatory markers including TNF-
α (hippocampus) [204,210], IL-6 (hippocampus) [204,210], and NFκB
(hippocampus) [204] were inhibited, and Jak/Stat pathway-related
genes including IL-15, IL-22, Socs2, and Socs5 [233] were suppressed.
Treatment altered oxidative stress-related markers indicated by a de-
crease in NO release [193,197] (hippocampus, cortex, cerebellum,
brain stem and spinal cord), MDA [193] (hippocampus, cortex, cerebel-
lum, brain stemand spinal cord), xanthine oxidase [193] (hippocampus,
cortex, cerebellum, brain stem and spinal cord), and an increase in CAT
(sciatic nerve sections) [194].
RSV treatment reversed the expression levels of genes related to
neurogenesis, neurotransmission, and synaptic plasticity: RSV up-
regulated Hdac4 and Wnt7a, while it down-regulated Hat1 and ApoE.
RSV treatment inhibited the enzymatic activities of acetylcholinesterase
(cerebral cortex synaptosomes [198] hippocampus [199], cerebral
cortex [199], striatum [199]).
RSV improved energymetabolism/mitochondrial biogenesiswith an
increase in the activity of AMP-activated protein kinase (metabolic reg-
ulator that promotes insulin sensitivity and energy production) andmi-
tochondrial number per neuron (hippocampus) [204].
In addition, treatment improved cerebrovascular dysfunction. Blood
vessel permeability [204] was decreased, and the responses/reactivity/
dilation of pial arterioles in response to ADP (eNOS-dependent agonist)
and N-methyl-D-aspartic acid (nNOS dependent agonist) [223] was
increased with diabetic rats.
5.7. Effects of RSV on the pancreas
Although there is a report that RSV treatment had no beneﬁcial ef-
fect on glucose tolerance or graft survival on mouse islet engraftment
[234]. RSV treatment protected beta cells from oxidative damage
while maintaining their function and structural integrity [211]. In rela-
tion to the oxidative stress, the increased levels of lipid peroxides, hy-
droperoxides, and protein carbonyls and the decreased activities of
SOD, CAT, GPx, and GST in diabetic pancreatic tissues were reversed
by RSV treatment [211]. RSV treatment prevented apoptosis with de-
creased levels of cleaved forms of caspase-3 and PARP in the beta cells
of the pancreas [235].
5.8. Effects of RSV on spleen
RSV treatment alleviated oxidative stress correlated with the down-
regulated levels of superoxide anion content, protein carbonyl, andMn-
SOD in STZ-induced diabetic spleen. However, RSV treatment showed
different effects on proinﬂammatorymarkers: RSV treatment decreased
NFκB and IL-1β, whereas it increased TNF-α and IL-6 [221].
5.9. Effects of RSV on the reproductive system
RSV treatment improved/restored erectile functionwith increases in
the intracavernous pressure to mean arterial pressure ratio [236],
smooth muscle to collagen ratio in cavernosum tissue [218], and
smoothmuscle content of the cavernosum [218] of STZ-induced diabet-
ic rats. Also, deregulated biomarkers in the corpora cavernosawere nor-
malized by RSV treatment. For instance, Sirt1 expression and SOD
activity were upregulated, whereas the expression of apoptotic p53
and oxidative stress-related FOXO3a was downregulated [236].
5.10. Effects of RSV on muscle/tendon
The reduced phosphorylation of Akt and GSK3 in both fast- and
slow-twitch muscles in diabetes was reversed by RSV treatment [237].
RSV treatment improved the process of tendon healing with a higherratio of newly synthesized collagen area to the healing region area
[238].
5.11. Effects of RSV on embryonic development
RSV suppressed diabetes-induced impairment during embryonic
development, along with reversal of decreased expression of retinoic
acid receptors, retinoid X receptors, and p-ERK1/2, and increased ex-
pression of p-c-Jun N-terminal kinase (JNK) and p-p38 [239].
6. Obesity
With animalmodels, obesity is induced by providing high-caloric diet
(e.g., excessive amount of dietary fat or sugar). Common markers for
obesity include body weight and fasting serum levels of glucose and in-
sulin. Of 13 studies [168,240–251], 11 [168,240–244,246,248–251] in-
clude a standard diet control. Among ten studies [168,240–244,
248–251] which provide the body weight of animals, eight with rat or
swine models showed signiﬁcant differences between standard diet
and obesity-inducing diet [168,248]. Notably, RSV treatment is reported
to reduce bodyweight [240,241,244,249] or have no effect [242,243,250,
251]. Eight [240–244,246,250,251] out of the abovementioned11 studies
[168,240–244,246,248–251] demonstrated that there is a signiﬁcant dif-
ference in glucose tolerance between standard diet and fat/sugar-
enriched diet controls. All eight studies [240–244,246,250,251] demon-
strated that RSV regimens (dose range: 30–400 mg/kg body weight/
day, duration: 1–20 weeks) improved glucose tolerance [240,242,243,
246,250,251] or lowered fasting glucose level [241,244] compared with
obese controls with mice or swine models. Among the eight studies
[240–244,248–250] providing fasting insulin levels in blood/serum, six
studies [240–244,250] showed that treatmentwith RSV decreased circu-
lating insulin in obese models using mice or pigs. However, a signiﬁcant
difference between a standard diet and a high-fat, high-sugar obese
model in Rhesus monkeys was not detected [248,249].
A summary of the results from animal studies related to obesity is
presented in Table 10. As illustrated by the trend analysis shown in
Fig. 3, based on 13 reports in the literature, there is a tendency for RSV
to improve glucose tolerance and decrease serum insulin, whereas al-
teration of body weight varies.
7. Central or peripheral nervous system diseases/disorders
In earlier studies (pre-2009), the neuroprotective properties of RSV
with various stimuli have been reported. Neurotoxicity induced by
kainic acid (excitotoxin) was alleviated by RSV treatment as judged by
recovery of glutamate decarboxylase (GAD) activity in olfactory cortex
and hippocampus [252], reduction in incidence of convulsions along
with brain MDA levels [253], attenuation of hippocampal neuronal
damage [254], and a decrease in activation of astrocytes and microglial
cells [254] in rats. In middle cerebral artery (MCA) occlusion-induced
cerebral ischemia models, RSV reduced the total volume of infarction
[255–258], suppressed motor impairment [256], improved necrotic
changes in the cortex and basal ganglia [259], ameliorated the neurolog-
ical deﬁcit [258], and decreased permeability of the blood–brain barrier
[258]. RSV decreased levels of MDA [256, 260], reduced glutathione
[256], MMP-9 in brain [259], TNF-α, andMPO activity [258], while it in-
creasedMMP-2 and VEGF [261]. Notably, RSV failed to protect the brain
in PPARα knockout mice [257], suggesting that the neuroprotective
mechanism of RSV is related to PPARα.
7.1. Effect of RSV on depression
According to a fact sheet from the World Health Organization
(WHO) in 2012, depression is a common worldwide mental disorder
with more than 350 million patients (http://www.who.int/
mediacentre/factsheets/fs369/en/). To evaluate the antidepressant
Table 10
Effect of RSV on diet-induced obesity in animal models (2009–2014).
Animal Obesity-inducing
model
Diet composition Treatment Standard diet (SD)
for comparison
with conditioned
diet
Route Dose (mg/kg
body
weight/day)
Duration (RSV
treatment/total
diet)
Body weight Glucose
tolerance,
serum
Insulin, serum Year Reference
Male C57BL/6
male mice
High-calorie diet
(HCD) for 14 weeks→
RSV treatment for
5 weeks with HCD
58% calories from fat Diet→ RSV Included Injection into
cerebral lateral
ventricles via
mini pump
79.2 ng/day 5/19 weeks Not affected Decreased
(fasting glucose)
Decreased 2009 [244]
Male Sprague–
Dawley rats
HCD for 6 weeks
with RSV
4.6 kcal/g, 200 g/kg sucrose,
195 g/kg lard, 30 g/kg
soybean oil
Diet + RSV Not included In diet 6, 30, 60 6/6 weeks Not affected Not affected Not affected 2009 [247]
Mice (wild type,
or deﬁcient in
AMPKα1 or -α2)
High-fat diet (HFD) 40% calories from fat Diet + RSV Not included In diet 400 12/12 weeks
(3 months)
Reduced (no
comparison
between SD and
HFD, no effect in
AMPKα1−/−mice)
Improved Decreased 2010 [245]
Male Yorkshire
miniswines
HCD/HFD 500 g of a hypercholesterolemic
diet daily, 4% cholesterol, 17.2%
coconut oil, 2.3% corn oil, 1.5%
sodium cholate
Diet + RSV Included In diet 100 11/11 weeks Body mass index
(reduced)
Improved Not available 2010 [251]
Male C57Bl/6J mice
(wild type, or
Glp1r−/−)
HFD 72% calories from fat Diet + RSV Included In diet 60 5/5 weeks Not available Improved Not available
(increased portal
plasma insulin)
2011 [246]
Yorkshire
miniswines
HCD/HFD 2248 kcal/day,
hypercholest-erolemic
diet, 4% cholesterol, 17.2%
coconut oil, 2.3% corn oil, 1.5%
sodium cholate
Diet + RSV Included In diet 100 11/11 weeks Reduced Improved Decreased 2011 [250]
Female and male
mini pigs
HFD
20% fat, 280 mg of cholesterol
in 100 g diet
Diet + RSV Included In diet 0.114 12/12 months No difference
from SD
No difference
from SD
Not available 2012 [168]
Male C57BL/6J mice HFD 60% fat in diet Diet + RSV Included In diet 200 20/20 weeks Not affected Improved Decreased 2012 [240]
Male C57BL/6 N
mice
HFD 58% calories from fat Diet→ RSV Included In diet 30 2/20 weeks Not affected Decreased
(fasting glucose)
Decreased 2012 [241]
Male C57BL/6J mice HFD Lard (30%, w/w) Diet→ RSV Included In diet 400 16/24 weeks Reduced Improved Decreased 2012 [243]
Rhesus monkeys High-fat, high-sugar
diet (HFSD)
42.3% calories from fat, 41.9%
calories from carbohydrate
(27% sucrose w/w)
Diet + RSV Included In diet 80 (1st yr)→
480 (2nd yr)
24/24 months No difference
from SD
No difference
from SD
No difference
from SD
2013 [248]
Rhesus monkeys HFSD 42% calories from fat, 27%
sucrose (w/w)
Diet + RSV Included In diet 80 (1st yr)→
480 (2nd yr)
24/24 months Not affected No difference
from SD
No difference
from SD
2013 [249]
Male Kunming
mice
HFD 50% calories from fat Diet + RSV Included In diet 200 12/12 weeks Reduced Improved Decreased 2014 [242]
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Fig. 3. Effects of RSV on glucose tolerance, serum insulin levels, and body weight with animal models used for studying obesity.
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been adopted including behavioral tests and biochemical/neurochemi-
cal assays. In behavioral tests, the clinical symptoms/signs of depression
including anhedonia (incapability to perform rewarded behaviors) and
helpless behaviors can be measured/quantiﬁed using a sucrose prefer-
ence test, forced swim test, tail suspension test, and shuttle box test
(learned helplessness model) [262]. In relation to pharmacological as-
pects, it has been reported that monoamine deﬁciency, alteration/
abnormality/dysfunction in hypothalamic–pituitary–adrenal (HPA)
axis, reduction in neurogenetic/neurotrophic-growth factor, and dys-
regulation in the brain immune system are observed in depression
models [263].
RSVwas reported to exert antidepressant-like effects through allevi-
ating depression-like symptoms/behaviors in rodent animal models.
RSV treatment improved the helplessness symptom as judged by reduc-
ing the duration of immobility in the tail suspension or forced swim-
ming tests in rats [264] and mice [265,266]. Also, under chronic stress
conditions, an increase in immobility time in both forced swim and
tail suspension tests [267], a decrease in sucrose preference [268], the
learned helplessness using the shuttle box method [268], and an in-
crease in adrenal gland/body weight [268], were reversed by RSV treat-
ment in rats.
In addition, RSV treatment altered molecular markers related to de-
pression. RSV induced brain-derived neurotrophic factor (BDNF)
levels in the hippocampus of unstressed rats [264] and mice [269],
as well as reversed the reduced expression of BDNF in the prefrontal
cortex and hippocampus of chronicmild stress-exposed rats [270]. In
addition, the reduced phosphorylation levels of cAMP response
element-binding protein (CREB) and ERK, which is involved in learn-
ing, memory, and neuroplasticity, were normalized by RSV in
stressed rats [270].
RSV can regulate the monoaminergic system. In the chronic stress
rat model, RSV attenuated the decrease in serotonin (hippocampus,
frontal cortex, hypothalamus), noradrenaline (hippocampus, frontal
cortex, striatum, hypothalamus), and dopamine (frontal cortex), and
the increase in monoamine oxidase-A (MAO-A) activity (hippocampus,
frontal cortex) [268]. These effects alsowere found in the normal condi-
tion ofmice: the levels of serotonin (hippocampus, frontal cortex, hypo-
thalamus), noradrenaline (hippocampus, frontal cortex), and dopamine
(frontal cortex)were increasedwhile the activities ofMAO-A andMAO-B (hippocampus, frontal cortex) were decreased [266]. In addition, it
was shown that the anti-immobility effect of RSVwas abolished by pre-
treatment with the serotonin antagonist para-chlorophenylalanine,
demonstrating the possible involvement of RSV on the serotonergic sys-
tem as related to its antidepressant potential [266].
Asmentioned above, hyperactivity of theHPA axis alongwithupreg-
ulated corticosterone in serum was observed in animal models for de-
pression. RSV reduced the upregulated serum concentration of
corticosterone, which is known to increase during stress in chronically
stressed-rats [267,270], as well as decreased serum corticosterone in
unstressed mice [269].7.2. Effect of RSV on epilepsy/seizure
Epilepsy affects about 50 million people worldwide. Reagents in-
cluding kainite and pentylenetetrazole (PTZ) have been used to induce
epileptic seizures in experimental animal models [271]. RSV reversed
biomarkers that are altered in epileptic rat models. S100 calcium bind-
ing protein B that is mainly produced by astrocytes and released into
serum and cerebral spinal ﬂuid is a useful biochemical marker to
evaluate brain damage after seizure [272]. RSV normalized the in-
crease of brain damage markers in epileptic models. RSV reduced
S100B protein levels in the cerebral spinal ﬂuid and serum [272],
neuron speciﬁc enolase levels in serum [273], and the expression of
caspase-3 (an apoptosis marker) [273] and kainate receptor of the
hippocampus [274] with PTZ-induced epileptic rats. Indeed, histo-
logical observations demonstrated a protective effect of RSV on dam-
age in CA1 [273,274], hilus [273], or CA3a [274] of the hippocampus.
In addition, altered oxidative stress parameters including increased
MDA levels, reduced glutathione levels and CAT activity in epileptic
brain of rats were reversed by RSV treatment [273]. Treatment with
RSV increased seizure latency (delayed the onset of seizure) [272]
and decreased seizure score [273].
The Morris water maze is used to measure the location memory
ability (spatial probe test), and spatial learning and memory ability
(place navigation test) [272]. RSV affected behavioral changes in epilep-
tic rats. Treatment led to recovery of impairment in location memory
ability [272] and spatial learning and memory ability [272], and de-
creased the number and rate of spontaneous seizures measured using
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demonstrate protective effects on juvenile epileptic rats [275].
7.3. Effect of RSV on Alzheimer's disease
Alzheimer's disease (AD) is characterized by intraneuronal
β-amyloid (Aβ) plaques and hyperphosphorylated tau, leading to neu-
ronal cell death and progressive memory loss. RSV reduces cognitive
impairment and has a neuroprotective role, decreasing the amyloid
burden and reducing tau hyperphosphorylation [276].
RSV increased the mean life expectancy and maximal lifespan in
SAMP8 (accelerated aging, a mouse model of sporadic and age-related
AD) as well as their controls, the related strain SAMR1 [276]. RSV sup-
plements (or RSV-fed animals) increased Sirt1 expression and conse-
quent downregulation of apoptotic protein p53 in the cortex and
hippocampus. Also, RSV supplements increased p-AMPK in the cortex
and total AMPK in the hippocampus [276].
RSV affected AD-relatedmarkers. The expression of a disintegrin and
metalloproteinase domain-containing protein 10 (ADAM10; possessing
α-secretase activity) was increased and the expression of p-tau
(Ser396) was decreased by RSV in the cortex and hippocampus. CDK5
protein levels and the p25/p35 ratio were decreased and p-GSK3β
(Ser9) was increased in the cortex, but not in the hippocampus. Levels
of Aβ plaques in the hippocampus were decreased in this mouse
model [276].
However, another study demonstrated that RSV neither improved
cognitive function nor increased the expression of Sirt1 and acetylated
p53 in the same mouse model [277]. This might be due to differences
between the two studies, including the starting point of diet, duration,
and dosage of RSV (e.g., starting at month 2 with 1 g/kg body weight
for 7 months of treatment vs. starting at month 5 with 0.12 g/kg body
weight for 2 months of treatment).
Aβ plaques are one of the unique features of AD. In animal models,
AD can be induced by the administration of Aβ peptide accompanied
by upregulation of iNOS and induction of HO-1 and neuronal apoptosis
[278]. RSV improved spatial memory (decreased escape latency in the
Morris water maze) with decreased accumulation of Aβ (25–35) and
lipid peroxidation in the hippocampus. The biomarkers iNOS and HO-
1, altered in Aβ-induced AD mice, were normalized by RSV [278].
Also, amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic
mice expressing a chimeric mouse/human APP, mutant human PS1, are
frequently used for AD studies. Both early (starting at 15 weeks of age)
[279] and late (at 50–53 weeks of age) [280] administration of RSV in
APP/PS1 mice demonstrated the therapeutic potential of RSV as judged
by altered biomarkers. Dietary RSV increased the expression of ACC
[279], drebrin [280], and transthyretin [280], as well as the phosphory-
lation of AMPK [279], GSK3β (Ser9) [280], and tau (Ser396, Ser404)
[280]. However, the effect on amyloid deposition differed fromprevious
work, possibly due to the different starting points of diet, dosage, and
duration.
7.4. Effect of RSV on Huntington's disease
Huntington's disease (HD) is caused by the mutation in
huntingtin (htt) gene with clinical symptoms of involuntary hyper-
kinetic movements. HD models can be established in animals by
toxins via inducing cell death either using excitotoxic agents includ-
ing quinolinic acid and kainic acid, or disrupting mitochondrial
machinery with 3-nitropropionic acid. Genetic models include trans-
genic mice such as R6/2, R6/1, N171-82Q, and YAC, or knock-in mice
including HdhQ92, HdhQ111, CAG140, and CAG15O [281].
Sirtuins are NAD-dependent deacetylases that regulate important
biologic processes including transcription, cell survival andmetabolism.
Activation of Sirt1, a mammalian sirtuin, extends longevity and in-
creases neuronal survival. An important substrate of Sirt1 is PGC-1α, a
principal regulator of energy metabolism, whose function issigniﬁcantly impaired in HD [282]. Administration of RSV (SRT501-M)
increased expression of PGC-1α, as well as its downstream targets, nu-
clear respiratory factor-1 and uncoupling protein-1, in brown adipose
tissue with the N171-82Q transgenic mouse model of HD [282].
7.5. Effect of RSV on Parkinson's disease
Parkinson's disease (PD) is a neurodegenerative disease that affects
about 1% of the population over 55 years of age. Animal models of PD
can be classiﬁed into neurotoxic [6-hydroxydopamine, 1-methyl-
1,2,3,6-tetrahydropiridine (MPTP), paraquat, rotenone], and genetically
mutated animal models (mutations in the genes encoding α-synuclein
and LRRK2, PINK1/Parkin, or DJ-1) [283]. Oxidative stress is a hallmark
in the pathogenesis of Parkinson disease (PD), which involves the selec-
tive loss of nigral dopaminergic neurons.
In one study, RSV protected dopaminergic neurons against MPTP-
induced cell degeneration almost to the same extent as PGC-1α overex-
pression [284]. RSV treatment demonstrated behavioral improvements
in PD animal models. RSV decreased abnormal rotational behavior in
rats [285,286] and increased motor coordination skills in 6-
hydroxydopamine-treated rats [287] and HtrA2 KO mice [288].
RSV showed neuroprotective effects in dopaminergic neurons with
an increased number of tyrosine hydroxylase (TH)-positive cells in stri-
atum and substantia nigra pars compacta in MPTP-treated mice [284]
and in the nigral area of 6-hydroxydopamine-treated rats [285,286]
along with an increase in dopamine and 3,4-dihydroxyphenylacetic
acid levels in striatum [287] and nigrostriatum [289]. RSV increased
the antioxidant activities in 6-hydroxydopamine-treated rats [286,
287]. TH is a rate-limiting enzyme in the synthesis of dopamine and is
only present in dopaminergic neurons of the nigra area.
7.6. Effect of RSV on memory function
RSV treatment has been reported to improve memory in behavioral
tests. Memory enhancement by RSV was blocked in Sirt1 mutant mice,
suggesting that RSV improves memory via a Sirt1-dependent pathway
[290].
Intraventricularlly-injected RSV ameliorated long-term memory
formation and LTP induction from hippocampus CA1 in 8–9 month-
old mice [290], and dietary treatment preserved cognitive function in
agingmice with an improved cerebrovascular condition (higher micro-
vascular density and a lower number of microvascular abnormalities),
and had no effect on cholinergic cell number or ﬁber density [291].
A protective effect of RSV against chronic alcohol-induced cognitive
dysfunction/deﬁcits, and impaired learning and memory in both adults
[292] and neonatal [293] rats, was reported to improved cognitive per-
formance (spatial memory) in homocysteine-induced oxidative stress,
apoptosis and cognitive impairment [294]. With the senescence-
accelerated mouse (SAM), improved learning andmemory ability, neu-
romuscular coordination, and sensorimotor capacity were reported
[295].
RSV treatment has also be invested in the following systems:
i) Prevention of memory decline in ovariectomized (OVX) rats chroni-
cally treatedwith D-galactose (D-gal) [296], ii) decreases in abnormality
of pyramidal cells in the hippocampal CA1 sub-region in OVX rats
chronically treated with D-gal [296], iii) prevention of CA1 cell injury
and improved cognitive deﬁcits in ischemia-exposed rats [297], iv)
amelioration of impaired spatial learning and memory in hypoxia–
ischemia-exposed neonatal rats [298], v) improved effects on learning
and memory by acting on muscarinic cholinergic receptors in
scopolamine- and mecamylamine-induced memory impaired rats
[299], and vi) increases in spontaneous locomotor activity, working
memory, and spatial memory performance in non-human primates,
mouse lemurs (Microcebus murinus) [300].
Along with memory improvement, RSV treatment altered
biochemical/molecular deﬁcits. Reports have appeared indicating
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ii) reduced acetylcholinesterase activity [292], iii) reduced levels of lipid
peroxidation, nitrite, TNF-α, IL-1β, nuclear NFκB p65, and caspase-3
[292], iv) recovery of reduced glutathione [292], v) increased SOD
[292] and CAT activities [292] in the cerebral cortex and hippocampus
of chronic ethanol-administered adult [292] and neonatal rats [293],
vi) reduced total homocysteine in plasma, reduced lipid peroxidase ac-
tivity, DNA fragmentation, p53 expression in the hippocampus in ho-
mocysteine (which is known to cause apoptosis and impairment of
neural plasticity in brain)-induced oxidative stress, apoptosis and cog-
nitive impairment in rats [294], vii) increased gene expression and ac-
tivity of SOD, and activity of GPx in the brain of SAM [295] and in the
serum of OVX rats chronically treated with D-gal [296], viii) decreased
MDA levels in the brain of SAM [295], and ix) decreased TBARS levels
in the serum and hippocampus in OVX rats chronically treated with D-
gal [296].
One study showed a negative effect of RSV in hippocampus-
dependent spatial learning and memory with reduction of p-CREB and
BDNF levels in the hippocampus [301].
7.7. Effect of RSV on ocular damage
RSV supplementation attenuated an increase in the expression of
Bcl-2 and VEGF in the retina of neonatal rats with oxygen-induced ret-
inopathy of prematurity [302]. Supplementation also shown to exert
protective effects by inhibiting pathological parameters including
TUNEL-positive retinal cells, outer nuclear layer thinning, and electro-
retinography changes in mice with light exposure (5000-lux white
light for 3 h)-induced retinal degeneration. RSV reduced the activation
of activator protein-1 and augmented Sirt1 activity in the retina [303].
RSV reduced the expression of eNOS and nNOS in an oxygen-induced
(hyperoxia) retinopathy model with rats [304].
RSV treatment attenuated decreased electroretinogram (ERG) b-
wave amplitudes, a loss of choline acetyltransferase indexing choliner-
gic amacrine cells, and increased vimentin levels (a marker of Müller
cells), together with inhibition of upregulated MMP-9, HO-1, and
iNOS, and recovery of downregulated Thy-1 (a marker of the neuron
retinal ganglion cells) in high intraocular pressure-induced retinal
ischemia with rats [305].
RSV treatment ameliorated impaired retinal functionwith increased
ERG a- and b-wave amplitudes, ischemia-mediated thinning of the
whole retina and, in particular, the inner retinal layers with a retinal is-
chemic injury model induced by elevation of intraocular pressure in the
rat [306].
RSV inhibits tunicamycin (ER stress inducer)-induced vascular
degeneration in the retina, together with inhibition of ER stress [down-
regulation of C/EBP homologous protein (CHOP), inositol-requiring
enzyme-1α (IRE1α), Bip]. In addition, RSV inhibits retinal I/R-induced
vascular degeneration, retinal I/R-induced upregulation of eukaryotic
translational initiation factor 2α (eIF2α)-CHOP branch of ER stress, up-
regulation of IRE1α and Xbp1 splicing, and overexpression of Bip [307].
RSV prevented a cigarette smoke-induced increase in choroidal
neovascularization following laser injury [308].
At the doses tested, no RSV effect was observed with the corneal
neovascularization experimental model of corneal alkali burn in white
Vienna rabbits [309].
7.8. Effect of RSV on nociceptive pain
RSV exhibited analgesic/antinociceptive effects in several animal
models. RSV treatment prevented the licking behavior in acute
nociceptionmodels induced by capsaicin or glutamate withmice. Inter-
estingly, RSV downregulated capsaicin-induced c-Fos and COX-2 ex-
pression in the spinal cord and COX-2 expression in the cortex [310].
Treatment reduced IL-6 or plantar incision-induced allodynia in the
mouse paw, and prevented the transition of allodynia to a chronicpain state (persistent noniceptive sensitization induced by PGE2) in
mouse paws [311].
RSV treatment attenuated mechanical allodynia and thermal
hyperalgesia, with increased Sirt1 and decreased acetyl-histone H3 ex-
pression in the spine in rats subjected to a neuropathic pain model of
chronic constriction injury (CCI) [312]. Spinal Sirt1 expression and
deacetylase activity decrease after CCI surgery. RSV pretreatment allevi-
ated CCI-induced neuropathic pain in mice, associated with thermal
hyperalgesia and mechanical allodynia, which was reversed by
intrathecal injection of the Sirt1 inhibitor EX-527, suggesting that the
analgesic effect of RSV is mediated by Sirt1 deacetylase activity [313].
RSV pretreatment resulted in an antinociceptive effect of long-term
morphine infusion induced antinociceptive/morphine tolerance in rats,
associated with reversal of the upregulated N-methyl-D-aspartate re-
ceptor subunit NR1 and NR2B subunits in the synaptosome fraction
and the postsynaptic density-95/NR1/NR2B complex in spinal cords.
RSV pretreatment suppressed proinﬂammatory cytokines (IL-1β, IL-6,
and TNF-α) in spinal cords [314].
7.9. Effect of RSV on other neuronal damage
RSV treatment resulted in varying neuroprotective outcomes with
different study models involving neonatal rodents. RSV treatment did
not prevent sevoﬂurane anesthesia-induced neuroapoptosis in neonatal
mouse (six-day-old mice) brain [315]. However, prenatal RSV treat-
ment alleviated early and late gestational stress-induced cognitive def-
icits/dysfunction in rats on postnatal day 40, without affecting reduced
cerebral Na+, K+-ATPase activitywhich is related tomemory consolida-
tion [316].
RSV pretreatment to postnatal day 7 rat pups resulted in neuropro-
tection against ethanol-induced cerebellar toxicity/damage with an
increase in the survival of cerebellar granule cells, a decrease in apopto-
tic events such as cleaved caspase-3 protein levels and terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive
cells, and a decrease in oxidative stress accompanied by increased levels
of glutathione, nuclear Nrf2, QR1, and SOD2, and decreased levels of
total thiol, MDA, and 8-iso-PGF2α (an oxidative stress marker for non-
enzymatic lipid peroxidation) in the cerebellum [317].
In an experimentalmodel of hypoxic-ischemic encephalopathywith
postnatal day 7 rat pups, RSV treatment normalized theperformances in
righting reﬂex, rotarod and water maze tests with a reduction of infarct
and preservation of myelination [298].
Chronic treatment of RSV attenuated disease onset and extended
survival of transgenic mice overexpressing G93A-SOD1 (mutant SOD,
a model of amyotrophic lateral sclerosis), with an increase in surviving
motor neurons, levels of Hsp25 and Hsp70, and a decrease in acetylated
heat shock factor 1 (HSF1) levels in spinal cords, demonstrating that the
protective effect of RSV is mediated by Sirt1 with the deacetylation of
HSF1 and subsequent upregulation of Hsps [318].
RSV exerted motor neuron protective activity. RSV abated
ﬂuphenazine-induced intensity of vacuous chewing movements, and
attenuated the reduction in both locomotor and exploratory activities
in an animal model of orofacial dyskinesia [319].
RSV exerted protective activity against neurodegenerative disorders.
RSV treatment reduced the levels of CD4+ T-helper 17 (TH17) cells (by
inhibiting the differentiation of CD4+ T lymphocytes to IL-17A-positive
TH17 cells), IL-17A andMMP-2, -3, and 9, and elevated the levels of tight
junction proteins (occludin and claudin-5) which improved Basso
Beattle Bresnahan locomotor rating scale integrity in Ppt1-KO mice
that mimic infantile neuronal ceroid lipofuscinosis [320].
RSV treatment i) alleviated fatigue symptoms with an increase in
daily running activity, neurogenesis, and hippocampal BDNF expres-
sion, and a decrease in hippocampus atrophy, neuronal apoptosis, and
hippocampal acetylated p53 expression in the fatigue mouse induced
by Brucella abortus antigen [321], ii) resulted in unfavorable effects on
hippocampal neurogenesis and cognitive function; RSV impaired
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proliferation and survival of neural progenitor cells in the dentate
gyrus of the hippocampus, associated with the elevated active form of
AMPK, and the reduced p-CREB and BDNF in the hippocampus [301],
iii) improved rat dorsal neuronal function with increased Basso Beattle
Bresnahan locomotor rating scale scores, restored neural morphology,
increased the number of neurons, increased SOD activity and Bcl-2 ex-
pression, and decreased MDA, IL-1β, IL-10, TNF-α, MPO, apoptosis
(TUNEL-positive cells, Bax, and caspase-3) in of spinal cord injured
rats [322], iv) elevated BDNF in the hippocampal tissues of rats [323],
and v) reduced infarct volumes during the acute phase of ischemic
stroke reducing brain injury in mice, with suppressed expression of IL-
1β and TNF-α, microglial activation, and ROS production in the ischemic
cortex (neuroprotective) [324].
RSV pretreatment prevented membrane lipid loss via reduction in
the total content of gangliosides, phospholipids, and cholesterol in the
hippocampi and cerebral cortex induced by global cerebral ischemia
(ischemia/reperfusion injury) in rats [325]. Pretreatment also inhibited
neuronal death, generation of ROS, lipid peroxidation and NO content
while it improved oxidative stress parameters (decreased SOD and
GPx, and increased CAT in the hippocampus; decreased SOD and the in-
creased CAT in the cortex), andNa+, K+-ATPase (susceptible to free rad-
ical attacks, decreased after cerebral ischemia and in various chronic
neurodegenerative disorders) activity in the cortex and hippocampus
of rats with global cerebral ischemia [326].
RSV treatment reduced ischemic cell death in the ﬁrst ischemic in-
sult (mild stroke) and in the recurrent insult (recurrent stroke).
Blood–brain barrier disruption and edema followed recurrent stroke
[327].
8. Aging
Although it is controversial, some papers have indicated that RSV
treatment can be beneﬁcial for extending lifespan, reduce the aging
process by inhibiting skin photoaging [38] caused by UV-B exposure,
increase insulin sensitivity in old mice [328], maintain T-cell compart-
ment and suppress proinﬂammatory markers in aging-hybrid mice
[329], preserve mitochondrial function upon high-fat diet [330],
enhance telomere length and telomerase activity in the aorta [331], im-
prove aerobic performance and exercise capacity [331], and decrease
oxidative stress/damage in the liver and skeletal muscle [332,333].
Topical application of RSV reduced hyperpigmentation (or sup-
pressed melanin) in UV-B-stimulated guinea pig skin, with a reduction
in skin tyrosinase-related protein 2 which is necessary for melanogene-
sis, supporting RSV as a potential depigmentation agent for treating
hyperpigmentation and skin photoaging [38].
RSV treatment did not increase survival rates in old mice fed either
standard diet or high-protein diet. Instead, RSV ameliorated insulin sen-
sitivity in old mice fed standard diet with a decrease in resistin levels.
However, RSV exhibited dual effects with an increase in serum inﬂam-
matory markers (CXCL1, and CCL5) and superoxide production and
with a decrease in aortic distensibility in old mice fed high-protein
diet [328].
RSV preserved the CD4+ and CD8+ T-cell compartment in
splenocytes of old mice (30-months-old) similar to that of young mice
(12-months-old). RSV treatment resulted in a reduction of proinﬂam-
matory cytokines such as IFN-γ, IL-6, and TNF-α, and attenuated oxida-
tive DNA damage with decreased 8-OHdG levels in the spleen of old
mice (30-month-old) [329].
RSV treatment induced the expression of Klotho which is known as
an aging suppressor gene in the mouse kidney [334].
Treatment with RSV improved the downregulated mitochondrial
biogenesis in the skeletal muscle and heart of mice fed a high-fat diet,
with an increase in citrate synthase activity, mtDNA copy number, and
mRNA expression of PGC-1α, mitochondrial mRNA expression of mito-
chondrial transcription factor A, and B2 (TFAM and TFB2M). The effectof RSV was abolished in animals lacking Sirt1, demonstrating that RSV
function is mediated by Sirt1 [330].
Although the treatment of low dose of RSV (0.0015 mg/kg of
chow) to rats for 6 months had no effect on lifespan, it resulted in in-
creased/improved aerobic capacity, time of exercise tolerance, and
endothelium-dependent relaxation by acetylcholine, with decreased
expression of p53 and increased telomere length and telomerase
activity in aortic tissue [331]. Treatment attenuated age-induced ox-
idative stress, with an increase in glutathione and GPx activity in the
liver of old mice [332], and with induction of Mn-SOD activity, and
reduction of hydrogen peroxide and lipid peroxidation levels in the
skeletal muscle of middle-aged mice [333].
On the other hand, some papers have reported that RSV has no sig-
niﬁcant effects on extending lifespan. For example, RSV had no effect
on the lifespan of genetically heterogeneous mice [335]. Similarly, RSV
supplementation (1.5 or 6 mg/mouse/day) from 12 months of age had
no signiﬁcant effect on survival in genetically heterogeneous mice
[336], nor did RSV extend themean lifespan ofWrnmutantmice lacking
the helicase domain of the WRN homolog [337].
9. Reproductive system diseases
RSV treatment has been reported to improve the reproductive ca-
pacity of female mice and male rabbits. Female (14–15-months-old)
mice supplemented with RSV for one year from 2 to 3-months-old
maintained fertility (to reproduce pups), with an increase in follicle
pool, number and quality of oocytes. Also, RSV treatment resulted in
an increase of telomerase activity, telomere length, and age-related
gene expression of Sirt1 which was reported to increase telomerase ac-
tivity, and a decrease of the senescencemarker p21 in ovaries, similar to
those of young mice (2–3-months-old) [338].
RSV treatment might improve erectile dysfunction induced by hy-
percholesterolemia, with increased vasorelaxation responses to acetyl-
choline in the corpus cavernosum isolated from cholesterol-fed male
rabbits [339].
RSV showed a protective effect on endometriosis. RSV treatment in
female rats with surgically induced endometriosis reduced implant
size and histological changes in the endometriotic foci, with a decrease
of VEGF levels in the peritoneal ﬂuid and plasma, MCP-1, levels in the
peritoneal ﬂuid, and VEGF (angiogenesis marker, angiogenesis as a
pathological alteration in endometriosis) expression in endometriotic
tissue [340].
RSV treatment in femalemicewith surgically induced endometriosis
resulted in a reduction in growthwith reduced PCNA- andKi67-positive
stromal and glandular cells, and a decrease in angiogenesis of
endometriotic lesions, with reduced microvessel density and CD31-
positive endothelial cells in the neovascular lesions [341].
However, itmay benecessary to be cautious about intake RSVduring
pregnancy. RSV treatment decreasedmaternalweight, placental inﬂam-
mation, and liver triglyceride deposition, while it increased glucose tol-
erance, and uterine artery volume blood ﬂow in pregnant nonhuman
primates. The fetal pancreatic mass was abnormally enlarged by RSV
treatment [342].
10. Irradiation injury
Total body irradiation (TBI) can lead to a decrease in survival, induc-
tion of bone marrow dysfunction and xerostomia. RSV exerted preven-
tive effects with rodents undergoing TBI. RSV pretreatment increased
survival, inhibited the reduction of WBCs and bone marrow nucleated
cells (BMNs), and improved hematopoietic progenitor cells (HPCs)
and hematopoietic stem cells (HSCs) with their clonogenic functions
in bone marrow in mice undergoing TBI-induced long-term bone mar-
row injury [343]. In relation to molecular alterations, after TBI, RSV
i) deceased ROS production and NOX4 expression, and increased
SOD2 and GPx-1 expression in HSCs and HPCs, ii) decreased p16 and
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iii) increased enzymatic activity of SOD2 and GPx-1 in BM-MNCs [343].
RSV treatment attenuated acinar loss, ductal damage and cell necro-
sis, with an increase in glutathione levels and a decrease inMDA in both
the parotid and submandibular glands of TBI-induced salivary gland
dysfunction model with rats [344].
11. Clinical studies
Early clinical studies conducted with RSV explored pharmacokinetic
properties to provide a rudimentary understanding of metabolism, bio-
availability, etc., with healthy subjects. More recently, as shown in Fig. 4,
the pharmacological features of RSV have been studied. Currently, the
majority of clinical studies focusmore on pharmacodynamics and, nota-
bly, clinical trials have been performed with overweight/obese,Fig. 4.Analysis of clinical trials conductedwith RSV. (A) A chronological trend of clinical studies
chart illustrating the health status of subjects participating in clinical trials, and (C) chronologidiabetic/metabolic syndrome, and cancer patients, as well as those
with cardiovascular disease. A summary of clinical studies with RSV is
listed in Table 11.11.1. Cancer
In patients with colorectal cancer who consumed RSV before surgi-
cal resection, tumor cell proliferation was reduced, suggesting that
RSV may serve as a colorectal cancer chemopreventive agent [345].
SRT501 (micronized RSV) supplementation with colorectal cancer and
hepatic metastases patients resulted in increased levels of cleaved
caspase-3 in malignant hepatic tissue [346]. However, SRT501 had no
effect on the levels of IGF-I, Ki-67, p-Akt (ser473), Akt1, p-GSK3, GSK3,
p-ERK, ERK, p-JNK, JNK, β-catenin, survivin, Bcl-2, Bax, or PARP [346].[pharmacokinetic-related studies (PK) vs. pharmacodynamic-related studies (PD)], (B) pie
cal trend of studies conducted with healthy patients vs. those with medical conditions.
Table 11
Effects of RSV in clinical trials (2009–2014).
Enrollment size (control/
intervention)
Participants condition Age(year) of RSV
group (range)
Study design Route Amount per day Duration Outcome Year Ref.
Cancer
20 Patients with histologically
conﬁrmed colorectal
cancer
66.8 ± 17.2
(46–83)
Not available Oral 0.5 or 1.0 g/day 8 days→ surgical
resection
Tumor cell proliferation (Ki-67)↓ 2010 [345]
9 (3/6) Patients with conﬁrmed
stage IV colorectal cancer
and hepatic metastases
had a life expectancy of
less than 3 months→
scheduled to undergo
resection of liver metastases
68.5 ± 10.8 (18
years
or older)
Pilot study, phase I,
randomized (2:1), double-
blind clinical trial
Oral (SRT501,
micronized
RSV
in water)
5.0 g/day ~14 days (10–21
days)→ surgical
resection
*Cleaved caspase-3 in
malignant hepatic tissue↑
*No signiﬁcant differences in IGF-I, Ki-67,
p-Akt (ser473), Akt1, p-GSK3,
GSK3, p-ERK,
ERK, p-JNK, JNK, b-catenin,
survivin, Bcl-2, Bax, and PARP
2011 [346]
39 Adult women at increased
breast cancer risk
Median age,
59.5 years in low
dosage and 54
years
in RSV high dosage
Randomized, double-blind,
placebo-controlled
Capsule P. cuspidatum with
5 or 50 mg of RSV,
twice per day
12 weeks *No signiﬁcant effect on the methylation
of 4 cancer-related genes (p16,
RASSF-1α, APC, CCND2)
*Positive correlation between RASSF-1α
methylation and nipple aspirate ﬂuid
(NAF) PGE2
2012 [347]
42 Healthy volunteers,
2 weeks of washout
40 (19–64) Not available Oral 1 g/day, once per day 4 weeks *CYP3A4, CYP2D6, and CYP2C9↓
*CYP1A2↑
2010 [348]
Cardiovascular
40 (20/20) Post-infarction Caucasian
patients (a history of
myocardial infarction)
66.3 ± 8.9
(42–80)
Double-blind, randomized,
placebo controlled trial
Capsule 10 mg/day 3 months *Left ventricular diastolic function↑
*Endothelial function measured by ﬂow-
mediated dilatation (FMD) of the brachial artery↑
*Low-density lipoprotein
(LDL) level↓
*Red blood cell deformability↑
*Platelet aggregation↓
*No changes in white cell count,
platelet count, CRP, HgbA1c, TNFα, total cholesterol,
triglyceride, HDL-cholesterol
2012 [349]
75 (25/25/25) Statin-treated patients in
primary cardiovascular
disease prevention
62 ± 9 Triple-blind, randomized,
placebo-controlled trial
Capsule 8 mg/day, daily RSV
enriched
grape extract (GE-RES),
grape extract (GE, similar
polyphenolic content
but no resveratrol), or
placebo (maltodextrin)
6 months *LDLox/ApoB↓ (more than GE)
*Non-HDL/ApopB↑ (more than GE)
*No changes in GGT, AST, ALT, LDH, ALP,
CPK, glucose, TSH, T4, bilirubin,
creatinine, urate, albumin
2012 [350]
75 (25/25/25) Patients on statin
treatment for 3 months
before inclusion
and diabetes mellitus or
hypercholesterolemia plus
another CV risk factor.
62 ± 9
(18 to 80)
Randomized, triple-blinded,
placebo controlled trial with
3 parallel arms
Capsule GE-RES (RSV 8 mg,
daily) for 6 months→
GE-RES (16 mg, daily)
for 6 months
12 months *Glucose, glycated hemoglobin↓(more than
GE)
*Decreases in high-sensitivity
CRP, TNF-α, PAI-1, and IL-6/IL-10 ratio
*IL-10↑
2012 [351]
1000 1000 participants in the
PREDIMED Study
(479 men and 521
women)
65.0 ± 5.4 Large cross-sectional,
parallel-group, multi-center,
controlled, randomized
clinical
Total
resveratrol
metabolite
(biomarker of
wine intake)
Not available Not available *Direct association between RSV
consumption and lower concentrations of
fasting blood glucose and triglycerides, also
lower heart rate
2012 [352]
75 (25/25/25) Stable-coronary artery disease patients Between 18 and
80 years
Triple-blind, randomized,
placebo-controlled, one-
year follow-up, 3-arm
pilot clinical trial
Capsule GE-RES (RSV 8 mg,
daily)
for 6 months→
GE-RES (16 mg, daily)
for
6 months
12 months *Glucose, GIHB↓ (better than GE)
*Anti-inﬂammatory serum adiponectin↑
*Thrombogenic PAI-1↓
*Activation of transcription factor Kruppel-
like factor 2 (KLF2)↑
*Inhibition of inﬂammation-related transcription
factors [activator protein 1 (Ap-1)], proto-
oncogene c-JUN (JUN), activating transcription
factor 2 (ATF-2), cAMP response element-binding
2013 [353]
(continued on next page)
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Table 11 (continued)
Enrollment size (control/
intervention)
Participants condition Age(year) of RSV
group (range)
Study design Route Amount per day Duration Outcome Year Ref.
(CREB)-binding protein
*Donwregulation of extracellular-space
acting genes related to inﬂammation, cell
migration and T-cell interaction signals in PBMCs
27 (13/14) Healthyindividuals 65 ± 1
(60–72)
Randomized double-
blind placebo
controlled design
Tablet 250 mg/day + high-
intensity exercise
training
8 weeks *Maximal oxygen uptake↓
*Interstitial level of vasodilator prostacyclin↓
*Muscle thromboxane synthase↑
*Abolished the positive effects of exercise on
low-density lipoprotein, total cholesterol/
high-density lipoprotein ratio and triglyceride.
*No alteration in the effect of exercise training
on the atherosclerosis marker VCAM-1, Sirtuin 1
2013 [354]
40 (20/20) Healthy individuals ≥18 years Double-blind, randomized,
placebo-controlled clinical
trial
NA 400 mg/day 30 days *Reduction of plasma IFN-γ and
fasting insulin concentration
2013 [355]
Diabetes
19 (9/10) Subjects with type 2
diabetes (T2DM)
57.9 ± 7.9 Double-blind, placebo-
controlled study
Oral 5 mg, twice/day, daily 4 weeks *Decreased insulin resistance, and
urinary ortho-tyrosine excretion.
*Increased the pAkt:Akt ratio in platelets.
*Had no effect on β-cell function.
2011 [356]
62 (29/28) Subjects with T2DM 56.67 ± 8.91 Open-label, randomized,
controlled trial
Oral 250 mg/day 3 months *Decreased the mean hemoglobin A(1c), systolic
blood pressure, low-density lipoprotein cholesterol
(LDL-C), total cholesterol, urea
nitrogen, and total protein in T2DM
*No effect on high-density
lipoprotein cholesterol (HDL-C)
2012 [357]
10 (0/10) Subjects with impaired
glucose tolerance
72 ± 3 Pilot study, randomized,
take open-label RSV
No control group
Oral 1, 1.5, and 2 g/day 4 weeks *Improved insulin sensitivity (Matsuda
index) and post meal plasma glucose.
*No changes in weight, blood pressure,
fasting plasma glucose and lipids
2012 [358]
24 (12/12) Obese subjects 44.7 ± 3.5 Investigator-initiated,
randomized, double
blinded, placebo-
controlled, parallel-
group trial
Oral Thrice
(500 mg × 3 =
1.5 g/day)
4 weeks *No changes in
NGlucose turnover and insulin sensitivity
NEndogenous glucose production and the turnover
NOxidation rates of glucose
NBlood pressure
NResting energy expenditure
NOxidation rates of lipid
NEctopic or visceral fat content
NInﬂammatory biomarkers:
TNFα, NFκB expression in adipose tissue
NMetabolic biomarkers: p-AMPK, p-acetyl-
CoA carboxylase, GLUT4, and PGC1α
expressions, and total acetylation status of
lysine residues in muscle
2013 [359]
35 (9/13/13 =
Placebo/GE/
GE-RES)
Hypertensive subjects
with type 2 diabetes
mellitus (T2DM)
63 ± 12 Randomized placebo-
controlled, triple-blind, dose-
response, 1-year follow-up
with three parallel arms
Oral GE-RES (RSV 8 mg),
daily
12 months *No changes in body weight, blood pressure,
glucose, HbA1c or lipids
*Altered biomarkers more signiﬁcantly than in
the GE group in comparison with placebo control.
NReduced ALP and IL-6 levels in serum
NReduced CCL3, IL-1β and TNF-α in PBMC
NIncreased LRRFIP-1 in PBMC
NIncreased miR-21, miR-663, miR-30c2
2013 [360]
24 (10/14) T2DM subjects with
diabetic foot syndrome
54.0 ± 10.1 Placebo-controlled,
examiner-blinded,
parallel-group
randomized controlled
pilot clinical
Oral 50 mg × 2/day 60 days *Reduced parameters reﬂecting diabetic
ulcer size
*Declined plasma ﬁbrinogen level
*No effect on CRP
2014 [361]
66 (31/33) Subjects with T2DM 52.45± 6.18 A randomized
placebo-controlled
Oral 1 g/day 45 days *Decreased systolic blood pressure, fasting
blood glucose, hemoglobin A1c, insulin,
2013 [362]
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double-blinded
parallel clinical trial
and insulin resistance
*Increased HDL
Obesity
19 (19/19) Overweight/obese with
elevated blood pressure
(BP) without diabetes
55 ± 2 Randomized, double-
blind, placebo-controlled,
crossover
human intervention trial
Oral RSV (resVida™)
30, 90 and
270 mg, weekly
1 h after
consumption
*Increased plasma RSV and ﬂow-mediated
dilatation of the brachial artery (FMD)
2011 [363]
11 (11/11) Obese without diabetes 52.5 ± 2.1 A randomized double-
blind, placebo-controlled,
crossover study
Oral resVida™ 150 mg/day 30 days *Reduced sleeping and resting metabolic
rate
*Decreased homeostasis model assessment
(HOMA) index
*Increased p-AMPK (Thr172),
SIRT1 and PGC-1α protein levels, citrate
synthase activity, muscle mitochondrial
respiration on a fatty acid-derived substrate
in muscle
*Increased intramyocellular lipid levels
*Decreased intrahepatic lipid
content, circulating glucose, triglycerides,
alanine-aminotransferase, leptin, and TNF-α
in plasma
2011 [364]
45 (14/15) Overweight,
postmenopausal
women without diabetes
58.2 ± 4.0 A randomized, double-
blind, placebo-controlled trial
Oral 75 mg/day 12 weeks *No effect on body composition, HOMA-IR
score, resting metabolic rate, blood
pressure, heart rate
*No effect on insulin sensitivity in the liver,
skeletal muscle, or adipose tissue
*No effect on AMPK, SIRT1, NAMPT, and
PPARGC1A, in either the skeletal muscle
or adipose tissue
*No effect on glucose, insulin, plasma lipids,
adiponectin, leptin, CRP,
IL-6 in plasma
2012 [365]
32 (10/12/10 =
RES/RTP/CGSE)
Obese subjects
without diabetes
36.5 ± 9.6 1 capsule per day of
placebo for 28 days→
150 mg RSV, 300 mg
RTP, or 400 mg CGSEf
for 28 consecutive days
Capsule 150 mg/day 28 days *Decreased GSH levels
*Increased anti-oxidized low-density
lipoproteins (oxLDL)
*Decreased PON3, CCR4, MAZ, and TFRC.
*Increased PRDX1, FTH1, CCL5, UBB, HYPB,
and HERPUD1
2012 [366]
28 (28/28) Obese subjects 61±1.3 (40-75) Randomized, double-
blind, placebo-controlled,
crossover
Oral 75 mg/day 6 weeks *FMD in the brachial artery↑
*No effects on blood pressure, arterial
compliance, and all components of the Stroop
Color-Word Test (maintaining
healthy circulatory function)
2013 [367]
10 Obese subjects 52 ± 2 Randomized, double-
blind, crossover design
Oral resveratrol
(Resvida®)
150 mg/day
30 days with
4 weeks washout
*No effect on fasting plasma concentrations
or postprandial plasma responses of
glucose-dependent insulinotropic
polypeptide, or glucagon-like peptide-1,
and incretin hormone levels
*Postprandial glucagon responses↓
2013 [368]
8 Overweight or obese
individuals with mild
to moderate
hypertriglyceridemia
45.8 ± 3.1 Randomized, double
blind, placebo-controlled,
crossover trial
Oral 1 g/day (500 mg
twice/day) for 1st
week, 2 g/day
(1 g twice/day) for
2nd week
2 weeks per
occasion (4–6
weeks
apart between
2 occasions)
*No effect on insulin sensitivity
*No effect on fasting or fed triglyceride
concentrations in plasma
*ApoB-48 production rate↓
*ApoB-100 production rate and fractional
catabolic rate↓
2013 [369]
46 (23/23) Overweight older
individuals
50–75 Not available Oral 200 mg/day 26 weeks *Hippocampal functional connectivity↑
*HbA1c and body
fat↓, leptin↑
*Memory performance↑
2014 [370]
Others
22 22 healthy adults,
9 healthy men
24.8
(21–29)
Randomized, double-blind,
placebo-controlled, crossover
Oral 250 or 500 mg 3 treatments
45 min before
*Cerebral blood ﬂow during task
performance↑
2010 [371]
(continued on next page)
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Table 11 (continued)
Enrollment size (control/
intervention)
Participants condition Age(year) of RSV
group (range)
Study design Route Amount per day Duration Outcome Year Ref.
study cognitive tasks
(7 days apart
between
occasions)
Patients affected by acne
vulgaris
18–23 Single-blind study, pilot Gel daily, 0.001% w/w 60 days *Global acne grading system score↓
*Lesions in areas↓
2011 [372]
12 Patients of reproductive
age with a laparoscopic
diagnosis of
endometriosis, who were
still reporting pain
and breakthrough bleeding
after the ﬁrst 6 months of
use of an oral contraceptive
containing drospirenone +
ethinylestradiol.
30 ± 5
(22–37)
Open ofﬁce-based study Oral 30 mg/day 2 months *Pain scores↓
*Dysmenorrhea and pelvic pain↓
2012 [373]
42 Patients pelvic pain and/or
infertility submitted to
laparoscopy and
hysteroscopy not only to
conﬁrm the diagnosis of
endometriosis but also to
treat the lesions
31 ± 4 (24–40) Immunohistochemistry
study
Oral 30 mg/day 2 months *Inhibition of aromatase and COX-2 expression in
eutopic
endometrium of patients
2012 [373]
50 Healthy adult smokers Randomized, double-blind,
placebo-controlled,
cross-over trial
Oral Group 1: 500 mg/day,
30 days→ washout,
30 days→ placebo 30
days
Group 2: placebo,
30 days→ washout,
30 days→ 500 mg/day,
30 days
30 days (total
90 days)
*CRP and triglyceride
concentrations↓
*Total antioxidant status values↑
*No changes in uric acid, glucose, insulin,
cholesterol, liver enzyme concentrations,
and weight, waist circumference, and
blood pressure values
2013 [374]
116 (29/29/29/
29 = G1/G2/
G3/CTL)
Most were in Canadian
Cardiovascular Society angina class
III at
inclusion (62%), 30% were
in class II, and 8% were in
class IV
65 (42–83) Randomized,
double-blinded,
active-controlled,
parallel clinical trial
Oral 20 mg/day 60 days *Left ventricular function marker
(N-terminal prohormone of brain natriuretic
peptide)↓
2013 [375]
783 783 community-dwelling
men and women 65 years
or older in 2 villages in
the Chianti area
65 years or older Prospective cohort
study
Not available None Year 1998–2009 No signiﬁcant alterations in serum CRP, IL-6,
IL-1β, and TNF
2014 [376]
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sor gene RASSF-1α which is directly related to a decrease in PGE2 in
adult women at increased breast cancer risk, demonstrating potential
chemopreventive effects [347]. Also, RSV supplementation inhibited
the phenotypic indices of CYP3A4, CYP2D6, and CYP2C9, while it
induced the phenotypic index of 1A2 [348].
11.2. Cardiovascular disease
RSV supplementation i) improved left ventricular diastolic function,
endothelial function measured by ﬂow-mediated dilatation, and red
blood cell deformability, and ii) decreased LDL levels and platelet
aggregation, and unfavorable hemorheological changes in patients
with coronary artery disease [349].
Stilvid® (RSV-enriched grape extract) supplementation exerted
cardioprotective activity by decreasing oxidized LDL and apolipoprotein-
B (ApoB) while increasing the ratio of non-HDLc (total atherogenic cho-
lesterol load)/ApoB in statin-treated patients for primary cardiovascular
disease prevention [350].
RSV-rich grape supplement (GE-RSV) improved inﬂammatory and
ﬁbrinolytic status,with a decrease in high-sensitivity C-reactive protein,
TNF-α, plasminogen activator inhibitor type 1, and IL-6/IL-10 ratio, and
an increase in anti-inﬂammatory IL-10, in patients who were on statins
for primary prevention of CVD and at high CVD risk [351].
With the analysis of total urinary RSV metabolites (TRMs) in 1000
participants, RSV consumption was correlated with beneﬁcial alter-
ations in blood lipid proﬁles, fasting blood glucose, and heart rate [352].
With stable-coronary artery disease patients, consumption of RSV-
containing grape extract (GE-RSV) resulted in an increase of the anti-
inﬂammatory serum adiponectin, and a decrease of thrombogenic
PAI-1, with downregulation of gene expression in peripheral blood
mononuclear cells (PBMCs) of: Connective tissue growth factor
(CTGF), cardiotrophin-like cytokine factor 1 (CLCF1), placental growth
factor (PGF), insulin-like growth factor binding protein 4 (IGFBP4), gas-
trin (GAST), melanoma inhibitory activity (MIA), wingless-type MMTV
integration site family member 10A (WNT10A), surfactant protein B
(SFTPB), collagen, type XVIII, alpha 1 (COL18α1), thyrotropin-releasing
hormone (TRH), IL-1β-3, -8, -13, -17A, -17C, and -24, chemokine (C–C
motif) ligand 3 (CCL3), CCL22, chemokine (C–X–C motif) ligand 2
(CXCL2), CXCL6, CX3CL1, sonic hedgehog (SHH), lymphotoxin alpha
(LTA), IFNβ1 and TNF [353].
RSV supplementation abolished the positive effects by physical exer-
cise training with i) a decrease in maximal oxygen uptake, interstitial
level of vasodilator prostacyclin, and ii) an increase in muscle throm-
boxane synthase, LDL, total cholesterol/HDL ratio and triglyceride con-
centrations in blood, without altering atherosclerosis marker VCAM-1
and Sirt1 [354].
RSV supplementation led to the reduction in plasma IFN-γ and
fasting insulin concentration [355].
11.3. Diabetes
In some cases, RSV treatment has been reported to improve insulin
sensitivity and glycemic control in type 2 diabetic patients. RSV treat-
ment for 4 weeks decreased insulin resistance (homeostasis model of
assessment for insulin resistance) and urinary ortho-tyrosine excretion,
while it increased the pAkt:Akt ratio in platelets. On the other hand, it
had no effect on parameters that relate to β-cell function
(i.e., homeostasis model of assessment of β-cell function) [356].
Treatment with RSV for 3 months improved mean hemoglobin
A(1c), systolic blood pressure, LDL cholesterol, total cholesterol, urea ni-
trogen, and total protein in type 2 diabetes mellitus (T2DM). No signif-
icant changes in body weight and HDL cholesterol were observed in
type 2 diabetes patients [357].
RSV treatment for 4 weeks improved glucose metabolism (fasting
plasma glucose was unchanged, but peak post meal and 3-hour glucoseAUC declined) in older adults with impaired glucose tolerance (IGT)
[358].
RSV supplementation for 4 weeks in obese subjects had no effect on
insulin sensitivity, endogenous glucose production and the turnover
and oxidation rates of glucose, blood pressure, resting energy expendi-
ture, oxidation rates of lipid, ectopic or visceral fat content, or inﬂamma-
tory (TNF-α and NFκB) and metabolic (p-AMPK, p-ACC, GLUT4, and
PGC-1α expressions) biomarkers [359].
RSV-enriched (8 mg) grape extract (GE-RSV) supplementation for
1 year showed beneﬁcial immunomodulatory effects in hypertensive
subjects with T2DM. GE-RSV treatment altered molecular markers
more thanGE treatmentwhen comparedwith placebo. GE-RSV reduced
serum inﬂammatorymarkers (ALP and IL-6 levels) and proinﬂammato-
ry cytokines [C–Cmotif chemokine ligand 3 (CCL3), IL-1β and TNF-α] in
PBMCs, while it increased the expression of the transcriptional repres-
sor [leucine-rich repeat ﬂightless-interacting protein 2 (LRRFIP-1)]
and miRNAs (miR-21, miR-663, miR-30c2) in PBMCs [360].
RSV treatment in type 2 diabetic patients with newly diagnosed
diabetic foot ulcers resulted in a reduction of diabetic ulcer size and
plasma ﬁbrinogen level [361].
RSV treatment exerted beneﬁcial effects on T2DM subjects with a
decrease in systolic blood pressure, fasting blood glucose, hemoglobin
A1c, and insulin resistance, and an increase in HDL [362].
11.4. Obesity
In obese subjects, RSV exhibited a vascular protective effect [363,
367], mimicked calorie restriction [364], had an antioxidant effect
[366], protected from deregulated glucose tolerance [368], had beneﬁ-
cial effects on hypertriglyceridemia [369], and improved memory per-
formance (maintenance of brain health) [370].
RSV consumption increased ﬂow-mediated dilatation of the brachial
artery, a biomarker of endothelial function and cardiovascular health, in
19 overweight/obese men or post-menopausal women [363].
RSV intakemodiﬁed clinical signs andmolecularmarkerswith obese
men, including a decrease in i) the sleeping and resting metabolic rate,
ii) homeostasismodel assessment (HOMA) index (an indication of insu-
lin sensitivity), iii) adipose tissue lipolysis and plasma fatty acid and
glycerol in the postprandial state, iv) intrahepatic lipid content, and
v) circulating glucose, triglycerides, alanine-aminotransferase, leptin
(satiety hormone), and TNF-α, and an increase in i) intramyocellular
lipid levels, ii) p-AMPK (Thr172), Sirt1, and PGC-1α protein levels, iii)
citrate synthase activity, and iv) muscle mitochondrial respiration on a
fatty acid-derived substrate [364].
RSV supplementation did not change i) body composition (intra-ab-
dominal fat volume and intrahepatic triglyceride content), ii) blood
pressure, iii) heart rate, iv) resting metabolic rate, and v) plasma
adipokine levels (adiponectin and leptin) or inﬂammatory markers
(C-reactive protein [CRP] and IL-6) insulin sensitivity in the liver, skele-
tal muscle, or adipose tissue in non-obese, postmenopausal women
with normal glucose tolerance [365].
RSV supplementation reduced oxidative stress related markers in
obese subjects. It decreased glutathione levels and increased oxidized
LDLs, with alterations of gene expression related to oxidative stress
and inﬂammation (decrease in PON3, CCR4, MAZ, and TFRC: increase
PRDX1, FTH1, CCL5, UBB, HYPB, and HERPUD1) [366].
In further clinical trials, RSV supplementation i) resulted in an in-
crease in ﬂow-mediated dilatation without affecting blood pressure, ar-
terial compliance, and all components of the Stroop Color-Word Test in
obese but otherwise healthy adults [367], ii) had no impact on the levels
of glucagon-like peptide-1, glucose-dependent insulinotropic polypep-
tide, and glucagon in fasting plasma, while it suppressed postprandial
plasma glucagon responses [368], iii) reduced the production rate of
triglyceride-rich apoB-48 and apoB-100 in overweight or obese individ-
uals with mild hypertriglyceridemia [369], and iv) improved memory
performance with an increase in functional connectivity between the
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proved glucose metabolism (decrease in HbA1c) in older adults [370].
11.5. Others
RSV treatment elevated cerebral bloodﬂowduring task performance
[371], reduced the Global Acne Grading System (GAGS) score (the aver-
age area of microcomedones) of lesions in the face area caused by acne
vulgaris [372], and reduced pain scores, with a decrease in dysmenor-
rhea and pelvic pain, in patients using oral contraceptiveswith endome-
triosis. RSV treatment also downregulated the expression of aromatase
and COX-2 in the eutopic endometrium of patients with endometriosis
and pelvic pain [373].
Finally, RSV treatment reduced CRP and triglyceride concentrations,
and increased Total Antioxidant Status values in healthy smokers [374],
and exhibited a beneﬁcial effect with a decrease in left ventricular func-
tion marker, N-terminal prohormone of brain natriuretic peptide (NT-
proBNP) with stable angina pectoris patients with asymptomatic or
symptomatic left ventricular dysfunction [375].
12. Discussion
As described herein, thousands of manuscripts have been published
describing some aspect of resveratrol action, and generally the results
are touted as correlating with some aspect of promoting better health.
With the labyrinth of in vitro studies, however, it is frequently difﬁcult
to rationalize an actual relationship with pharmacological relevance
since high concentrations of the parent compound are necessary tome-
diate a response. In most cases, achievable serum concentrations are
many orders of magnitude below the concentrations used with in vitro
studies. On the other hand, concentrations of metabolites such as RSV-
3-O-glucuronide may be higher [262], and the mean plasma level of
RSV itself can be enhanced by processes such as micronization [263].
Also, recent studies have suggested that improvements in RSV bioavail-
ability can be realized through combination with other compounds. For
example, co-treatment with piperine improved the bioavailability of
RSV, increased maximum serum concentrations in mice [377], exerted
a synergistic antidepressant-like effect with a mouse model [265], andFig. 5. Effect of RSV on molecular targets (biomarkers) detenhanced bioefﬁcacy on cerebral blood ﬂow in human subjects [378].
In addition, many other factors come into play, such as enzymatic re-
conversion of RSV metabolites to the parent compound and the effect
of combining RSVwith other drugs or compounds, so clearly, additional
work is required.
Although all of this is interesting from an academic or practical
point-of-view, detailed discussion of such topics is beyond the scope
of the current review. In this review, we have concentrated on results
obtainedwith animalmodels and clinical trials involving human beings.
The ultimate endpoint of greatest interest is the biological responseme-
diatedwith a livingmammal and, frankly, the array of responses report-
ed over the past 5 years is simply amazing (Fig. 5). Amelioration of
disease states and modulation of biomarkers is widespread over a
large range of ailments. In many cases the in vivo investigations de-
scribed herein allude to possible mechanisms, such as antioxidant,
anti-inﬂammatory, and Sirt1 signal-activating capacities, but in actual
fact it is difﬁcult to pinpoint one truly critical target. Rather, it appears
that the ability of RSV to mediate an overall response involves the
weak modulation of a host of targets. As described previously, RSV is
an extremely promiscuous molecule [379]. Taking advantage of this
multifaceted pharmacological mode of action, additional uses of RSV
have been suggested, such as exploitation as a probe for the rapid detec-
tion of Aβ and monitoring AD [380].
Considering the broad range of responses, it is tempting to view RSV
as a panacea. It should be borne in mind, however, the effects are often
statistically signiﬁcant but relatively weak, so a deﬁnitive response or
cure is not a reasonable expectation. This leads to the notion of creating
analogs with greater potency and efﬁcacy [381], but of course such an
approach leads to greater developmental expenses, greater risk, and
possibly adverse side-effects. It is noteworthy that RSV itself has not
been found to exert adverse effects in animal models or clinical inter-
vention studies.
As a distractor, a recent prospective cohort study, conducted in two
villages in the Chianti area of Italy, revealed that total urinary RSV me-
tabolite concentration did not correlate with inﬂammatory markers
(serum CRP, IL-6, IL-1β, and TNF), cardiovascular disease, and cancer,
nor was it predictive of all-cause mortality in 65-year-old or older sub-
jects [376]. However, since this work is based on dietary levels, whichermined with in vivo models of various disease states.
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ative conclusions could be drawn in regard to the other 1600 com-
pounds associated with the grape [7], which are also present at very
low concentrations, as well as the myriad of remaining constituents as-
sociated with the diet of free-living human beings.
In sum, to reach any deﬁnitive statements regarding the therapeutic
potential of resveratrol, more detailed clinical trials with well-deﬁned
material and protocols are necessary. ClinicalTrials.gov lists approxi-
mately 80 RSV trials (https://clinicaltrials.gov/ct2/search/browse?
brwse=intr_alpha_r; accessed September 9, 2014), so perhaps ﬁrmer
expectations will be delineated over the next few years.
Abbreviation list
Aβ β-Amyloid
ACC Acetyl-CoA carboxylase
ACF Aberrant crypt foci
AD Alzheimer's disease
δ-ALA-D Aminolevulinic acid dehydratase
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AMPK 5′ AMP-activated protein kinase
AOM Azoxymethane
APP Amyloid precursor protein
AR Androgen receptor
AST Aspartate aminotransferase
BP Benzo[a]pyrene
BPDE BP diolepoxide
BDNF Brain-derived neurotrophic factor
CAT Catalase
CCL2 Chemokine (C–C motif) ligand 2
COX-2 Cyclooxygenase-2
CREB cAMP response element-binding protein
CRP C-reactive protein
CVD Cardiovascular disease
CX3CL Chemokine (C–X3–C motif) ligand
DEN Diethylnitrosamine
DMBA 7,12-Dimethylbenz[a]anthracene
DMH 1,2-Dimethylhydrazine
DSS Dextran sulfate sodium
DR Death receptor
EMT Epithelial to mesenchymal transition
eNOS Endothelial nitric oxide synthase
ERG Electroretinogram
ERK Extracellular signal-regulated kinase
FABP fatty-acid binding protein
FAS Fatty acid synthase
FOXC2 Forkhead box protein C2
FOXO Forkhead transcription factors of the O class
GLUT Glucose transporter
GSH Glutathione, reduced state
GPx-1 Glutathione peroxidase 1
GR Glutathione reductase
GSK3β Glycogen synthase kinase 3β
GST Glutathione S-transferase
γ-GT γ-Glutamiltransferase
HBV X Hepatitis B virus X protein
HD Huntington's disease
HDL High-density lipoprotein
HIF-1α Hypoxia-inducible factor 1-alpha
4-HNE 4-Hydroxy-2-nonenal
HO-1 Heme oxygenase-1
HPA Hypothalamic–pituitary–adrenal
HPC Hematopoietic progenitor cells
HSC Hematopoietic stem cells
HSF Heat shock factor 1Hsp Heat shock protein
IGF-1 Insulin-like growth factor 1
IGFBP Insulin-like growth factor binding protein
I/R Ischemia/reperfusion
IκB Inhibitor of kappa B
ICAM-1 Intercellular adhesion molecule 1
IL Interleukin
iNOS Inducible nitric oxide synthase
i.p. Intraperitoneal
IRS Insulin receptor substrate
i.v. Intravenous
JNK c-Jun N-terminal kinase
KC Keratinocyte-derived chemokine
LDH Lactate dehydrogenase
LDL Low-density lipoprotein
LKB1 Liver kinase B1
LPL Lipoprotein lipase
L-NAME NG-Nitro-L-arginine methyl ester
5-LOX 5-Lipoxygenase
MAO Monoamine oxidase
MCP-1 Monocyte chemoattractant protein-1
MDA Malondialdehyde
MMP-9 Metalloproteinase 9
MPO Myeloperoxidase
MPTP 1-Methyl-1,2,3,6-tetrahydropiridine
MTA1 Metastasis-associated protein 1
mTOR Mammalian target of rapamycin
MNU N-Methyl-N-nitrosourea
NFκB Nuclear factor kappa B
NO Nitric oxide
NQO NAD(P)H: quinone oxidoreductase
Nrf2 Nuclear factor (erythroid-derived 2)-like 2
8-OHdG 8-Hydroxy-2′-deoxyguanosine
O-GlcNAc O-Linked β-N-acetylglucosamine
OVX Ovariectomized
p- Phosphorylated
PAI-1 Plasminogen activator inhibitor-1
PARP Poly ADP ribosyl polymerase
PBMNC Peripheral blood mononuclear cells
PCNA Proliferation cell nuclear antigen
PD Parkinson's disease
PGC-1α Peroxisome proliferator-activated receptor gamma co-
activator-1alpha
PGES-1 Prostaglandin E synthase-1
PKC-β2 Protein kinase C-β2
PPAR Peroxisome proliferator-activated receptor
PS1 Presenilin 1
PSA Prostate-speciﬁc antigen
PTZ Pentylenetetrazole
RBF Renal blood ﬂow
RBP4 Retinol binding protein 4
ROS Reactive oxygen species
RSV Resveratrol
S6K S6 kinase
SAM Senescence-accelerated mouse
SAP Severe acute pancreatitis
s.c. Subcutaneous
SHRs Spontaneously hypertensive rats
Sirt1 Sirtuin 1
SOCS1 Suppressor of cytokine signaling 1
SOD Superoxide dismutase
STAT3 Signal transducer and activator of transcription 3
STZ Streptozocin
TBARS Thiobarbituric acid reactive substances
TBI Total body irradiation
TH Tyrosine hydroxylase
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TPA 12-O-Tetradecanoylphorbol-13-acetate
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end
labeling
VCAM-1 Vascular cell adhesion molecule 1
VEGF Vascular endothelial growth factor
VLDL Very-low-density lipoprotein
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